An Investigation of the Molecular Mechanisms Underlying the Analgesic Effect of Jakyak-Gamcho Decoction: A Network Pharmacology Study

Ho-Sung Lee,1,2 In-Hee Lee,1 Kyungrae Kang,2 Sang-In Park,3 Tae-Wook Kwon,2 and Dae-Yeon Lee1,2

1The Fore, 87 Ogeum-ro, Songpa-gu, Seoul 05542, Republic of Korea
2Forest Hospital, 129 Ogeum-ro, Songpa-gu, Seoul 05549, Republic of Korea
3Forestheal Hospital, 173 Ogeum-ro, Songpa-gu, Seoul 05641, Republic of Korea

Correspondence should be addressed to Dae-Yeon Lee; foresthrnd@gmail.com

Received 9 October 2020; Revised 5 November 2020; Accepted 24 November 2020; Published 4 December 2020

Academic Editor: Xia Wang

Herbal drugs have drawn substantial interest as effective analgesic agents; however, their therapeutic mechanisms remain to be fully understood. To address this question, we performed a network pharmacology study to explore the system-level mechanisms that underlie the analgesic activity of Jakyak-Gamcho decoction (JGd; Shaoyao-Gancao-Tang in Chinese and Shakuyaku-Kanzo-To in Japanese), an herbal prescription consisting of Paeonia lactiflora Pallas and Glycyrrhiza uralensis Fischer. Based on comprehensive information regarding the pharmacological and chemical properties of the herbal constituents of JGd, we identified 57 active chemical compounds and their 70 pain-associated targets. The JGd targets were determined to be involved in the regulation of diverse biological activities as follows: calcium- and cytokine-mediated signalings, calcium ion concentration and homeostasis, cellular behaviors of muscle and neuronal cells, inflammatory response, and response to chemical, cytokine, drug, and oxidative stress. The targets were further enriched in various pain-associated signalings, including the PI3K-Akt, estrogen, ErbB, neurotrophin, neuroactive ligand-receptor interaction, HIF-1, serotonergic synapse, JAK-STAT, and cAMP pathways. Thus, these data provide a systematic basis to understand the molecular mechanisms underlying the analgesic activity of herbal drugs.

1. Introduction

Pain is a major healthcare and socioeconomic issue worldwide that severely affects the overall health, quality of life, daily activities, and productivity of patients, and it places a substantial financial burden on healthcare systems and society [1–6]. Based on the pathophysiological mechanisms, pain is classified into (i) nociceptive and (ii) nonnociceptive neuropathic pain [7–21]. Nociceptive pain is caused by the activation and stimulation of nociceptors and pain pathways driven by inflammation, chemicals, or physical events, and it is subdivided into somatic and visceral [7–21]. Neuropathic pain develops due to damage, injury, dysfunction, or disease of the somatosensory nervous system, and it is further classified into central and peripheral [7–21]. At present, opioid analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and non-anti-inflammatory antipyretic analgesic agents serve as primary therapies for pain alleviation [6, 15, 22–28]. However, current treatment options for pain management are still associated with limited efficacy and unwanted adverse effects [6, 15, 22–28]. Meanwhile, herbal drugs and multicomponent-multitarget-multipathway polypharmacological therapeutics have received considerable attention for pain treatment because of their important analgesic effects with fewer side effects and toxicity [29–36].

Jakyak-Gamcho decoction (JGd; Shaoyao-Gancao-Tang in Chinese and Shakuyaku-Kanzo-To in Japanese) is an herbal drug that consists of Paeonia lactiflora Pallas and...
Evidence-Based Complementary and Alternative Medicine

2. Materials and Methods

2.1. Screening of Active Chemical Compounds in Jakayak-Gamcho Decoction. Information on chemical compounds comprising the herbal constituents of JGd was investigated using the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database [80]. Then, based on their absorption, distribution, metabolism, and excretion (ADME) properties (i.e., oral bioavailability (OB), Caco-2 permeability, and drug-likeness (DL)), chemical compounds that satisfy the following criteria were screened and determined to be bioactive as previously suggested [63, 80, 81] using the TCMSP [80]: OB $\geq$ 30%, Caco-2 permeability $\geq$ 0.4, and DL $\geq$ 0.18. In brief, OB is the proportion of orally administered drug compounds that enter the general circulation, and it is one of the most crucial considerations in the design and development of a drug [80, 82]. Of note, compounds with an OB larger than 30% are commonly regarded as effectively absorbed in the human body [80, 82]. Caco-2 permeability is an important index for the investigation of intestinal permeability and drug efflux that is based on an evaluation of the rate of absorption and diffusion of a compound across Caco-2 human intestinal cells [80, 83–85]. In general, a chemical compound is considered not permeable in the intestinal epithelium if its Caco-2 permeability is lower than –0.4 [86, 87]. DL is a widely used measurement that qualitatively assesses whether a certain compound is physicochemically and structurally suitable for use as a drug [80, 88]. Note that the average DL of all drugs is 0.18, and therefore, it is commonly used as the threshold to determine the pharmacological potential of a compound [80, 88].

2.2. Target Identification. Human targets of the active chemical compounds of JGd were investigated using various databases and models, including the PharmMapper [89], search tool for interactions of chemicals (STITCH) 5 [90], Swiss Target Prediction [91], similarity ensemble approach (SEA) [92], systematic drug targeting tool (SysDT) [93], and weighted ensemble similarity (WES) [94]. The pain-associated human genes and proteins were investigated from the DisGeNET [95], Therapeutic Target Database [96], GeneCards [97], Comparative Toxicogenomics Database [98], Human Genome Epidemiology Navigator [99], Online Mendelian Inheritance in Man [100], Pharmacogenomics Knowledge-base [101], and DrugBank [102], using the medical subject headings term “Pain” (ID: D010146) for Homo sapiens species.

2.3. Network Construction. The herbal medicine-active chemical compound (H-C), active chemical compound-target (C-T), and target-pathway (T-P) networks were generated by connecting the herbal medicines with their active chemical compounds, the compounds with their targets, and the targets with the signaling pathways in which they are enriched. The protein-protein interaction (PPI) network was generated using the STRING database (interaction confidence score $\geq$ 0.9) [103]. Analysis and visualization of networks were performed with Cytoscape software [104]. A network is composed of nodes (e.g., herbal medicines, chemical compounds, targets, or pathways) and edges (or links) describing the interactions among the nodes [105]. The degree is defined as the number of links of a node [105].

2.4. Contribution Index Evaluation. The network-based efficacy-based contribution index (CI) of active chemical
compounds of JGd was evaluated following previous procedures as follows [81]:

\[
\text{NE}(j) = \sum_{i=1}^{n} d_i, \\
\text{CI}(j) = \frac{c_j \times \text{NE}(j)}{\sum_{i=1}^{m} c_i \times \text{NE}(i)} \times 100%,
\]

where \( m \) is the number of chemical compounds, \( n \) is the number of targets of chemical compound \( j \), \( d_i \) is the number of links of target \( i \) of chemical compound \( j \), and \( c_i \) (or \( c_j \)) is the number of previous studies having "pain" and component \( i \) (or \( j \)) in their title or abstract searched from the PubMed database (https://pubmed.ncbi.nlm.nih.gov/). The chemical compounds with the highest CIs were regarded as contributing more to the pharmacological activity of a certain herbal drug [81].

2.5. Functional Enrichment Analysis. Gene ontology (GO) enrichment analysis was performed with g:Profiler [106]. Pathway enrichment analysis was performed with Kyoto Encyclopedia of Genes and Genomes database [107]. Functional association analysis was conducted using GeneMANIA [108].

2.6. Molecular Docking Analysis. The structures of chemical compounds of JGd and their targets were obtained from the PubChem [109] and RCSB Protein Databank [110] databases, respectively. Then, the molecular docking scores between the chemical compounds and the targets were assessed using AutoDock Vina [111]. Of note, a certain chemical compound is regarded as having high binding affinity to a target if the corresponding docking score is less than or equal to \(-5.0\) [112, 113].

3. Results

The network pharmacology study for the exploration of analgesic mechanisms of JGd was conducted as follows (Figure 1). Detailed information regarding the chemical constituents of JGd was obtained from the comprehensive biomolecular databases, and the bioactive compounds were investigated using their ADME characteristics (Figure 1). The human targets of the active chemical compounds were identified from various databases and models that assess chemical-protein interactions (Figure 1). Then, we integrated the extensive herbal drug-related data into networks and performed network pharmacology analysis (Figure 1).

3.1. Active Chemical Compounds of Jakyak-Gamcho Decoction. Detailed information regarding the chemical compounds present in JGd was obtained from TCMSP [80] (Supplementary Table S1), and the active compounds were defined as those with OB \( \geq 30\% \), Caco-2 permeability \( \geq -0.4\), and DL \( \geq 0.18 \), as described previously [63, 80, 81]. Some components were also determined to be active because of the substantial amount contained in JGd and their reported relevant pharmacological activity [42, 57, 114–128], although they did not meet the criteria. As a result, 111 active chemical compounds were obtained for JGd (Supplementary Table S2).

3.2. Targets of Jakyak-Gamcho Decoction. We identified the targets of the active chemical compounds of JGd using the following databases and models for the investigation of chemical-protein interactions: Swiss Target Prediction [91], STITCH 5 [90], PharmMapper [89], SEA [92], SysDT [93], and WES [94]. Therefore, 70 human pain-associated and 137 nonpain-associated targets were obtained for JGd (Supplementary Table S3).
3.3. Network Pharmacology-Based Analysis of Jakyak-Gamcho Decoction. To perform network pharmacology-based analysis of the pharmacological features of JGd, we constructed an herbal medicine-active chemical compound-target (H-C-T) network composed of 129 nodes (two herbal medicines, 57 active chemical compounds, and 70 pain-associated targets) and 217 links (Figure 2 and Supplementary Table S3) using comprehensive information regarding the herbal drug. We found that quercetin (number of targets = 36) and kaempferol (number of targets = 11) have relatively many targets (Figure 2 and Supplementary Table S3), implying that they might be important active compounds for the therapeutic activity of JGd. In addition, 27 human genes/proteins were found to be targeted by two or more active chemical compounds of JGd (Figure 2), suggesting a poly-pharmacological mechanism.

To investigate the biological interaction relationship between the JGd targets, we generated a PPI network (58 nodes and 174 links) comprising the targets (Figure 3). Next, we searched for hubs, specific nodes with a high degree in the network that are shown to have crucial biological functions and promising therapeutic potential [129, 130]. In the analysis, hubs were determined as nodes for which the degree was greater than or equal to twice the average node degree of the network [131, 132]. The results showed that PIK3R1 (degree = 25), HSP90AA1 (degree = 15), EGFR (degree = 14), AKT1 (degree = 13), LPAR1 (degree = 13), LPAR2 (degree = 13), and LPAR3 (degree = 13) were hubs (Figure 3), implying that they might be the key targets responsible for the analgesic activity of JGd. These hubs were shown to be involved in the regulation of pain-related processes and could function as potent targets to induce analgesic effects. The PIK3R1 gene was suggested to have the potential to function as a pain-related regulator according to the genetic interaction analysis [133], and its expression level might be associated with osteoarthritis pathogenesis [134]. Upregulation of the HSP90AA1 gene was observed in patients with fibromyalgia [135–137], and pharmacological inhibition of heat shock protein 90 (HSP90; encoded by HSP90AA1) was shown to alleviate monoarthritis-induced pain [138]. The activation of epidermal growth factor receptor (EGFR; encoded by EGFR) and AKT (encoded by AKT1) is associated with the development and enhancement of diverse types of pain, and their therapeutic modulation might be associated with analgesic properties [139–156]. Lysophosphatidic acid receptor 1 (encoded by LPAR1) activity is involved in pain behavior arising from bone cancer, inflammation, diabetes, and neuropathy, and its pharmacological or genetic ablation might reduce the pain response [157–165]. Lysophosphatidic acid receptor 3 (encoded by LPAR3) plays crucial roles in the development and maintenance of neuropathic pain, and its blockade exerts analgesic effects [163, 166, 167].

We further assessed the CIs of the active chemical compounds of JGd to assess their pharmacological contribution to the analgesic effect of the herbal drug as described earlier [81, 168]. As a result, quercetin was shown to have the highest CI (91.83%) (Supplementary Figure S1), which suggests that this chemical compound might be the primary contributor to the analgesic activity of JGd.

Together, these data indicate the system-level pharmacological properties of the analgesic activity of JGd.

3.4. Functional Enrichment Investigation of Jakyak-Gamcho Decoction Networks. To investigate the molecular mechanisms underlying the analgesic effect of JGd, we carried out GO enrichment analysis of the targets. As a result, the JGd targets were enriched in GO terms involved in the modulation of a variety of biological activities, such as calcium- and cytokine-mediated signalings, calcium ion concentration and homeostasis, cellular behaviors of muscle and neuronal cells, inflammatory response, and response to chemical, cytokine, drug, and oxidative stress (Supplementary Figure S2), which are in accordance with the previously reported molecular mechanisms of the herbal drug [40, 41, 44, 46, 49, 55, 58–60, 169–172]. In addition, GeneMANIA analysis indicated that the JGd targets might functionally interact via diverse mechanisms (Supplementary Figure S3), implying the similarity in their pharmacological roles.

Because various signaling pathways were reported to be associated with the initiation, transmission, perception, and maintenance of pain [12, 14, 19, 20, 144, 155, 173–186], we carried out pathway enrichment analysis. We found that the JGd targets were enriched in the following signalings: “PI3K-Akt signaling pathway,” “Neuroactive ligand-receptor interaction,” “Estrogen signaling pathway,” “cAMP signaling pathway,” “Chemokine signaling pathway,” “JAK-STAT signaling pathway,” “Neurotrophin signaling pathway,” “AMPK signaling pathway,” “Dopaminergic synapse,” “ErbB signaling pathway,” “HIF-1 signaling pathway,” “Insulin signaling pathway,” “mTOR signaling pathway,” “Serotonergic synapse,” “Adipocytokine signaling pathway,” “Drug metabolism - cytochrome P450,” “IL-17 signaling pathway,” “TNF signaling pathway,” “Arachidonic acid metabolism,” and “VEGF signaling pathway” (Figure 4 and Supplementary Figure S2). These signalings are well-known pain-regulating pathways and function as therapeutic targets of analgesic and pain-relieving drugs. The activities of adenosine monophosphate-activated kinase (AMPK), ErbB, mammalian target of rapamycin (mTOR), phosphoinositide 3-kinase (PI3K)-Akt, tumor necrosis factor (TNF), or vascular endothelial growth factor (VEGF) signaling pathways are involved with the development and maintenance processes of various types of pathological pain, and their functional modulation might relieve neuropathic, nociceptive, and bone cancer pain [144, 149, 150, 155, 156, 187–226]. Furthermore, the activity of PI3K-Akt and the adipocytokine pathway further correlates with the severity of neuropathic and inflammatory pain, and their targeting agents exert analgesic effects [227–229]. The estrogen pathway serves as a modulator of the processing and sensitivity of visceral and mechanical pain responses [230–235]. Previous studies have shown the involvement of cyclic adenosine monophosphate (cAMP), chemokine, Janus kinase (JAK-) signal transducer and activator of transcription (STAT), neurotrophin, and hypoxia-inducible factor (HIF) pathways in the initiation and persistence of inflammatory, cancer, and neuropathic pain, as well as their role as pharmacological mediators of analgesic approaches [141, 224, 236–265].
impaired regulation of insulin signaling might promote the development of and pain sensation with diabetic neuropathy, which can be alleviated by its functional restoration [266–269].

The interleukin- (IL-) 17 pathway plays a crucial role in cellular mechanisms of pain pathogenesis and maintenance in various diseases including multiple sclerosis, prostatitis, intervertebral disk degeneration, femoral head osteonecrosis, and neuropathy; its inhibition might block the generation and persistence of pain [270–282]. Arachidonic acid metabolism is associated with the generation and secretion of diverse biomolecular substances.

Figure 2: The herbal medicine-active chemical compound-target network of Jakyak-Gamcho decoction. Green nodes, herbal medicines; red nodes, active chemical compounds; blue nodes, pain-related targets.

Figure 3: The protein-protein interaction network for the pain-related targets of Jakyak-Gamcho decoction. Blue nodes, pain-related targets.
responsible for the induction of inflammation and pain, and it is mainly involved in the mechanisms of action of NSAIDs [283–288]. Moreover, the serotonergic and dopaminergic synapse pathways are key neurotransmitters responsible for modulating the intensity and duration of pain, and their therapeutic interventions have been shown to attenuate pain behaviors [289–292].

Collectively, these results demonstrate the molecular- and pathway-level mechanisms underlying the analgesic activity of JGd.

3.5. Molecular Docking Evaluation. To investigate the binding potential of the chemical compounds of JGd components for the targets, we evaluated their molecular docking activity. As a result, 95.09% of the binding interactions between the active chemical components of JGd and the hub targets was found to have docking scores equal to or lower than −5.0 (Figure 5 and Supplementary Table S4), indicating their therapeutic binding potential. Of note, the protein structures for LPAR2 and LPAR3 were unavailable in the RCSB Protein Databank [110]; therefore, they were excluded from the analysis.

4. Discussion

Herbal medicines are increasingly being acknowledged as effective analgesic and pain-relieving agents owing to their promising therapeutic activity with fewer side effects [29–36]. JGd is a well-known herbal drug that alleviates pain induced by multiple diseases such as peripheral neuropathy, myalgia, arthralgia, and diabetes [30, 37–40, 44, 46–48], and it is one of the most frequently prescribed oral analgesics in East Asia [56]. Previous studies have attempted network pharmacology analyses to investigate the mechanisms underlying JGd for the treatment of osteoarthritis and Parkinson’s disease [293, 294]; however, its network-perpective analgesic properties have not been fully elucidated. Therefore, this network pharmacology study attempted to investigate system-level mechanisms that underlie the analgesic activity of JGd. The ADME evaluation and network pharmacology investigation identified 57 active chemical compounds in JGd and their 70 pain-associated human molecular targets. Further enrichment analysis indicated that JGd targets were enriched with GO terms related to the modulation of biological activities, involving calcium- and cytokine-mediated signalings, calcium ion concentration and homeostasis, cellular behaviors of muscle and neuronal cells, inflammatory response, and response to chemical, cytokine, drug, and oxidative stress, consistent with the previously reported molecular mechanisms of the herbal drug [40, 41, 44, 46, 49, 55, 58–60, 169–172]. We further showed that JGd might target various pain signalings to exert its analgesic and pain-relieving effects, which involve the PI3K-Akt, estrogen, ErbB, neurotrophin, neuroactive ligand-receptor interaction, HIF-1, serotonergic synapse, JAK-STAT, and cAMP pathways.

The analgesic activity of the chemical components of JGd has been previously reported. (+)-Catechin and pinocembrin produce analgesic, antineuropathic, and antinociceptive effects [295–297]. Albiflorin might play a pharmacological role as an analgesic, antineuropathic, and antinociceptive compound that can reduce pain intensity via the functional modulation of calcium channels, mitogen-activated protein kinase (MAPK) pathways, and various cytokines and chemokines [127, 298]. Moreover, formononetin, glabridin, glycyrrhizin, and paenol exhibit anti-inflammatory, antinociceptive, and analgesic activities by inhibiting the generation of inflammatory cytokines and signaling molecules, thereby attenuating the pain responses [117, 120, 299–302]. Gallic acid could also have potential anti-
inflammatory, antioxidant, and neuroprotective effects that could improve neuropathic pain, neuronal damage, and injury [119, 303, 304]. Glycyrrhizin and naringenin reduce inflammatory and neuropathic pain-like behaviors by modulating the secretion of inflammation-associated cytokines and mediators, as well as the activities of cyclic guanosine monophosphate (cGMP) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signalings [120, 301, 305–314]. Iso-liquiritigenin was reported to possess analgesic, antispasmodic, and relaxant properties [315, 316]. Isorhamnetinamelioratesthe pain intensity of diabetic neuropathy via its neuroprotective, antioxidative, and anti-inflammatory effects [317]. Kaempferol shows anti-inflammatory, antioxidant, and analgesic effects, which relieve the pain symptoms of gastritis, pancreatitis, and diabetic neuropathy [318–320]. In addition, liquiritigenin might suppress neuropathic pain by improving thermal, cold, and mechanical hyperalgesia [116]. Mairin (betulinic acid) has been shown to exert anti-inflammatory, antinociceptive, antipyretic, and analgesic effects, thereby alleviating visceral pain and chemotherapy-, infection-, and diabetes-associated neuropathies [321–326]. Quercetin reduces pain arising from inflammation, cancer, chronic prostatitis/chronic pelvic pain syndrome, arthritis, and muscle injury by inhibiting the induction of oxidative stress and activating inflammatory and adrenergic pathways, neurotransmitters, and cytokines [327–334]. In addition, quercetin further modulates the activity of a variety of pathways, including Toll-like receptor, mTOR, protein kinase Cε (PKCε)-TRPV1, p70 ribosomal S6 kinase (p70S6K), and P2X receptors, as well as oxidative stress- and inflammation-associated mediators to exert its analgesic effects against diverse types of neuropathic pain [214, 335–347]. β-Sitosterol shows analgesic, antinociceptive, and anti-inflammatory activities [348–353]. These studies regarding the chemical components of JGd provide the pharmacological basis for the analgesic activities of this herbal drug.

Based on the network pharmacological analyses, the following studies would contribute to the improvement of herbal drug therapies: (i) an assessment of the therapeutic efficacy of JGd analgesic activity in specific diseases that are associated with distinct types of pain, such as cancer, osteoarthritis, myalgia, arthralgia, and diabetes; (ii) a comprehensive exploration of the system-level mechanisms of analgesic properties of the herbal drug from diverse pharmacological perspectives, involving antinociceptive, anti-inflammatory, muscle relaxant, and antipyretic effects; and (iii) an investigation of the safety and effectiveness of combined treatment with JGd and widely used analgesic agents, including celecoxib, tramadol, and acetaminophen [24, 56, 354].

To conclude, we investigated the systems’ perspective pharmacological properties of JGd, a widely prescribed analgesic herbal drug [56]. Based on the network pharmacological approach, we investigated 57 active chemical compounds and their 70 pain-related targets responsible for the analgesic activity of JGd. The targets of JGd were associated with the modulation of biological functions such as calcium- and cytokine-mediated signalings, calcium ion concentration and homeostasis, cellular behaviors of muscle and neuronal cells, inflammatory response, and response to chemical, cytokine, drug, and oxidative stress, which suggests the molecular mechanisms of JGd treatment. In addition, the enrichment analysis indicated that the targets are involved in various pathways that are associated with the pathophysiology of pain, including the PI3K-Akt, estrogen, ErbB, neurotrophin, neuroactive ligand-receptor interaction, HIF-1, serotonergic synapse, JAK-STAT, and cAMP pathways. The overall data offer a novel systematic view of the polypharmacological characteristics of herbal drugs and a mechanistic basis for their clinical implications for pain treatment.

**Data Availability**

The data used to support the findings of this study are included within the article and supplementary materials file.
Conflicts of Interest
The authors declare that there are no conflicts of interest.

Supplementary Materials
Supplementary Figure S1: contribution index analysis for the analgesic activity of active chemical compounds of Jakayak-Gamcho decoction. Supplementary Figure S2: functional enrichment analyses for the pain-associated targets of Jakayak-Gamcho decoction. Supplementary Figure S3: functional interaction analysis of the pain-associated targets of Jakayak-Gamcho decoction. Supplementary Table S1: list of the chemical compounds contained in Jakayak-Gamcho decoction. Supplementary Table S2: list of the active chemical compounds contained in Jakayak-Gamcho decoction. Supplementary Table S3: list of the targets of active chemical compounds of Jakayak-Gamcho decoction. Supplementary Table S4: docking scores of the active chemical compounds of Jakayak-Gamcho decoction with the hub targets. (Supplementary Materials)

References
[1] L. C. Goudas, R. Bloch, M. Gialeli-Goudas, J. Lau, and D. B. Carr, “The epidemiology of cancer pain,” Cancer Investigation, vol. 23, no. 2, pp. 182–190, 2005.
[2] G. J. Macfarlane, “The epidemiology of chronic pain,” Pain, vol. 157, no. 10, pp. 2158-2159, 2016.
[3] M. M. Russo and T. Sundaramurthi, “An overview of cancer pain control,” Clinical Gastroenterology and Hepatology, vol. 9, no. 11, pp. 2543–2546, 2011.
[4] B. H. Smith and N. Torrance, “Epidemiology of neuropathic pain and its impact on quality of life,” Current Pain and Headache Reports, vol. 16, no. 3, pp. 191–198, 2012.
[5] C. L. Stucky, M. S. Gold, and X. Zhang, “Mechanisms of pain,” Proceedings of the National Academy of Sciences, vol. 98, no. 21, pp. 11845-11846, 2001.
[6] A. Wolkerstorfer, N. Handler, and H. Buschmann, “New approaches to treating pain,” Bioorganic & Medicinal Chemistry Letters, vol. 26, no. 4, pp. 1103–1119, 2019.
[7] J. A. Butera, “Current and emerging targets to treat neuropathic pain,” Journal of Medicinal Chemistry, vol. 50, no. 11, pp. 2543–2546, 2007.
[8] A. Chakravarty and A. Sen, “Migraine, neuropathic pain and nociceptive pain: towards a unifying concept,” Medical Hypotheses, vol. 74, no. 2, pp. 225–231, 2010.
[9] L. Colloca, T. Ludman, D. Bouhassira et al., “Neuropathic pain,” Nature Reviews Disease Primers, vol. 3, Article ID 17002, 2017.
[10] J. B. Epstein, D. J. Wilkie, D. J. Fischer, Y.-O. Kim, and D. Villines, “Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy,” Head & Neck Oncology, vol. 1, no. 1, p. 26, 2009.
[11] R. Freynhagen, H. A. Parada, C. A. Calderon-Ospina et al., “Current understanding of the mixed pain concept: a brief narrative review,” Current Medical Research and Opinion, vol. 35, no. 6, pp. 1011–1018, 2019.
[12] S. P. Hunt and P. W. Mantyh, “The molecular dynamics of pain control,” Nature Reviews Neuroscience, vol. 2, no. 2, pp. 83–91, 2001.
[31] T. Kono, N. Mamiya, N. Chisato et al., “Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer,” Evid Based Complement Alternat Med, vol. 2011, Article ID 418481, 8 pages, 2011.

[32] Y. Luo, C.-Z. Wang, R. Sawadogo, T. Tan, and C.-S. Yuan, “Effects of herbal medicines on pain management,” The American Journal of Chinese Medicine, vol. 48, no. 1, pp. 1-16, 2020.

[33] M. Nishikio, M. Shimada, N. Kurita et al., “The kampo medicine, goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen,” International Journal of Clinical Oncology, vol. 16, no. 4, pp. 322-327, 2011.

[34] M. Tawata, A. Kurihara, K. Nitta, E. Iwase, N. Gan, and T. Onaya, “The effects of goshajinkigan, a herbal medicine, on subjective symptoms and vibratory threshold in patients with diabetic neuropathy,” Diabetes Research and Clinical Practice, vol. 26, no. 2, pp. 121-128, 1994.

[35] B. Yanju, L. Yang, B. Hua et al., “A systematic review and meta-analysis on the use of traditional Chinese medicine compound kushen injection for bone cancer pain,” Supportive Care in Cancer, vol. 22, no. 3, pp. 825-836, 2014.

[36] C.-S. Yuan, S. R. Mehendale, C.-Z. Wang et al., “Effects of Corydalis yanhusuo and Angelicae dahuricae on cold presor-induced pain in humans: a controlled trial,” The Journal of Clinical Pharmacology, vol. 44, no. 11, pp. 1323-1327, 2004.

[37] K. Fujii, S. Okamoto, K. Saitoh et al., “The efficacy of shakuyaku-kanzo-to for peripheral nerve dysfunction in paclitaxel combination chemotherapy for epithelial ovarian carcinoma,” Gan To Kagaku Ryoho, vol. 31, no. 10, pp. 1537-1540, 2004.

[38] H. Fujinami, S. Kajiura, T. Ando, H. Mihara, A. Hosokawa, and T. Sugiyama, “Direct spraying of shakuyakukanzoto onto the duodenal papilla: a novel method for preventing pancreatitis following endoscopic retrograde cholangiopancreatography,” Digestion, vol. 91, no. 1, pp. 42-45, 2015.

[39] K. Takahashi and M. Kitao, “Effect of TJ-68 (shakuyaku-kanzo-to) on polycystic ovarian disease,” International Journal of Fertility and Menopausal Studies, vol. 39, no. 2, pp. 69-76, 1994.

[40] S. Tsuji, K. Yasuda, G. Sumi et al., “Shakuyaku-kanzo-to inhibits smooth muscle contractions of human pregnant uterine tissue in vitro,” Journal of Obstetrics and Gynaecology Research, vol. 38, no. 7, pp. 1004-1010, 2012.

[41] K. Yamamoto, H. Hoshiai, and K. Noda, “Effects of shakuyaku-kanzo-to on muscle pain from combination chemotherapy with paclitaxel and carboplatin,” Gynecologic Oncology, vol. 81, no. 2, pp. 333-334, 2001.

[42] T. Yoshida, T. Sawa, T. Ishiguro, A. Horiba, S. Minatoguchi, and H. Fujinawa, “The efficacy of prophylactic shakuyaku-kanzo-to for myalgia and arthralgia following carboplatin and paclitaxel combination chemotherapy for non-small cell lung cancer,” Supportive Care in Cancer, vol. 17, no. 3, pp. 315-320, 2009.

[43] I. C. Chen, T. H. Lin, Y. H. Hsieh et al., “Formulated Chinese medicine shaoyao gancao tang reduces tau aggregation and exerts neuroprotection through anti-oxidation and anti-inflammation,” Oxid Med Cell Longev, vol. 2018, Article ID 9595741, 16 pages, 2018.

[44] H. Fujinami, S. Kajiura, T. Ando, H. Mihara, A. Hosokawa, and T. Sugiyama, “Direct spraying of shakuyakukanzoto onto the duodenal papilla: a novel method for preventing pancreatitis following endoscopic retrograde cholangiopancreatography,” Digestion, vol. 91, no. 1, pp. 42-45, 2015.

[45] N. Kaifuchi, Y. Omiya, H. Kushida, M. Fukutake, H. Nishimura, and Y. Kase, “Effects of shakuyakukanzoto and its absorbed components on twitch contractions induced by physiological Ca2+ release in rat skeletal muscle,” Journal of Natural Medicines, vol. 69, no. 3, pp. 287-295, 2015.

[46] T. Onaya, “The effects of goshajinkigan, a herbal medicine, on subjective symptoms and vibratory threshold in patients with diabetic neuropathy,” Diabetes Research and Clinical Practice, vol. 26, no. 2, pp. 121-128, 1994.

[47] K. K. Lee, Y. Omiya, M. Yuzuriha, Y. Kase, and H. Kobayashi, “Antispasmodic effect of shakuyakukanzoto extract on experimental muscle cramps in vivo: role of the active constituents of Glycyrrhizae radix,” Journal of Ethnopharmacology, vol. 145, no. 1, pp. 286-293, 2013.

[48] J. J. Liu, Y. Cheng, Y. y. Shao et al., “Comparative pharmacokinetics and metabolites study of seven major bioactive components of shaoyao-gancao decoction in normal and polycystic ovary syndrome rats by ultra high pressure liquid chromatography with tandem mass spectrometry,” Journal of Separation Science, vol. 42, no. 15, pp. 2534-2549, 2019.

[49] Y. Y. Shao, Z. P. Chang, Y. Cheng et al., “Shaoyao-Gancao decoction alleviated hyperandrogenism in a letrozole-induced rat model of polycystic ovary syndrome by inhibition of NF-kB activation,” Bioscience Reports, vol. 39, no. 1, Article ID BSR20181877, 2019.

[50] F. Sui, H.-Y. Zhou, J. Meng et al., “A Chinese herbal decoction, shaoyao-gancao tang, exerts analgesic effect by down-regulating the TRPV1 channel in a rat model of arthritic pain,” The American Journal of Chinese Medicine, vol. 44, no. 7, pp. 1363-1378, 2016.

[51] K. Takahashi and M. Kitao, “Effect of TJ-68 (shakuyaku-kanzo-to) on polycystic ovarian disease,” International Journal of Fertility and Menopausal Studies, vol. 39, no. 2, pp. 69-76, 1994.
[57] L.-M. Feng, Y.-Y. Chen, D.-Q. Xu et al., “An integrated strategy for discovering effective components of shaoyao gancao decoction for treating neuropathic pain by the combination of partial least-squares regression and multi-index comprehensive method,” *Journal of Ethnopharmacology*, vol. 260, Article ID 113050, 2020.

[58] Y. Omiya, Y. Suzuki, M. Yuzurihara et al., “Antinociceptive effect of shakuyakukan-zoto, a kampo medicine, in diabetic mice,” *Journal of Pharmacological Sciences*, vol. 99, no. 4, pp. 373–380, 2005.

[59] J. Zhou, Q. Wang, Z. Xiang et al., “Network pharmacology to uncover the molecular mechanism of action of traditional Chinese medicine formula,” *Biomolecules*, vol. 9, no. 8, p. 362, 2019.

[60] H. S. Lee, I. H. Lee, S. I. Park, and D. Y. Lee, “Network pharmacology-based investigation of the system-level molecular mechanisms of the hematopoietic activity of Samul-Tang, a traditional Korean herbal formula,” *Biomolecules*, vol. 9, no. 8, p. 362, 2019.

[61] Y. Wang, B. Dong, W. Xue et al., “Anticancer effect of radix astragali on cholangiocarcinoma in vitro and its mechanism via network pharmacology,” *Medical Science Monitor*, vol. 26, Article ID e921162, 2020.

[62] T. Xu, Q. Wang, and M. Liu, “A network pharmacology approach to explore the potential mechanisms of huangqin-baihuo herb pair in treatment of cancer,” *Medical Science Monitor*, vol. 26, Article ID e923199, 2020.

[63] S. Q. Zhang, H. B. Xu, S. J. Zhang, and X. Y. Li, “Identification of the active compounds and significant pathways of Artemisia annua in the treatment of non-small cell lung carcinoma based on network pharmacology,” *Medical Science Monitor*, vol. 26, pp. e923624-1–e923624-11, 2020.

[64] Z. Hu, M. Yang, L. Yang et al., “Network pharmacology-based identification of the mechanisms of Shen-Qi compound formula in treating diabetes mellitus,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2020, Article ID 5798764, 15 pages, 2020.

[65] Y. Jiang, M. Zhong, F. Long, and R. Yang, “Deciphering the active ingredients and molecular mechanisms of Tripterygium hypoglaucum (Levl.) hutch against rheumatoid arthritis based on network pharmacology,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2020, Article ID 2361865, 9 pages, 2020.

[66] D. H. Li, Y. F. Su, C. X. Sun, H. F. Fan, and W. J. Gao, “A network pharmacology-based identification study on the mechanism of Xiao-Xu-Ming decoction for cerebral ischemic stroke,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2020, Article ID 2507074, 8 pages, 2020.

[67] W. Liu, Y. Fan, C. Tian et al., “Deciphering the molecular targets and mechanisms of HGWD in the treatment of rheumatoid arthritis via network pharmacology and molecular docking,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2020, Article ID 7151634, 13 pages, 2020.

[68] H. Qian, Q. Jin, Y. Liu et al., “Study on the multitarget mechanism of sanmiao pill on gouty arthritis based on network pharmacology,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2020, Article ID 9873739, 11 pages, 2020.

[69] B. Ren, L. Tan, Y. Xiong et al., “Integrated analysis of the mechanisms of Da-Chai-Hu decoction in type 2 diabetes mellitus by a network pharmacology approach,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2020, Article ID 9768414, 21 pages, 2020.

[70] W. Wang, Y. Zhang, J. Luo, R. Wang, C. Tang, and Y. Zhang, “Virtual screening technique used to estimate the mechanism of Adhatoda vasica nees for the treatment of rheumatoid arthritis based on network pharmacology and molecular docking,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2020, Article ID 5872980, 12 pages, 2020.

[71] K. Yao, K. Li, S. Long, C. Kong, and S. Zhu, “Potential molecular mechanisms of Chaihu-Shugan-San in treatment of breast cancer based on network pharmacology,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2020, Article ID 3670309, 9 pages, 2020.

[72] K. Yang, L. Zeng, and J. Ge, “Exploring the pharmacological mechanism of Danzhzi Xiao Yao powder on ER-positive breast cancer by a network pharmacology approach,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2018, Article ID 5059743, 20 pages, 2018.

[73] C. Zhang, Y. Liao, L. Liu et al., “A network pharmacology approach to investigate the active compounds and mechanisms of musk for ischemic stroke,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2020, Article ID 4063180, 14 pages, 2020.

[74] J. Zhou, Q. Wang, Z. Xiang et al., “Network pharmacology analysis of traditional Chinese medicine formula Xiao Ke Yin Shui treating type 2 diabetes mellitus,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2019, Article ID 4202563, 15 pages, 2019.

[75] J. Lu, P. Li, J. Wang et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” *Journal of Cheminformatics*, vol. 6, p. 13, 2014.

[76] Y. Yue, L. T. Xin, Y. C. Fan et al., “Herb pair Danggui-Honghua: mechanisms underlying blood stasis syndrome by system pharmacology approach,” *Scientific Reports*, vol. 7, Article ID 40318, 2017.

[77] C. K. Wang and D. J. Craik, “Cyclic peptide oral bioavailability: lessons from the past,” *Biopolymers*, vol. 106, no. 6, pp. 901–909, 2016.

[78] Y. Kono, A. Iwasaki, K. Matsuoka, and T. Fujita, “Effect of mechanical agitation on cationic liposome transport across the blood-brain barrier by the application of ultrasonic waves,” *Biopolymers*, vol. 106, no. 6, pp. 901–909, 2016.
expression by paeonol through the MAPKs inactivation in RAW 264.7 cells," The American Journal of Chinese Medicine, vol. 37, no. 1, pp. 181–194, 2009.

[116] L. Chen, W. Chen, X. Qian, Y. Fang, and N. Zhu, "Liquiritigenin alleviates mechanical and cold hyperalgesia in a rat neuropathic pain model," Scientific Reports, vol. 4, Article ID 5676, 2014.

[117] T.-C. Chou, "Anti-inflammatory and analgesic effects of paeonol in carrageenan-evoked thermal hyperalgesia," British Journal of Pharmacology, vol. 139, no. 6, pp. 1146–1152, 2003.

[118] L. Dong, L. Yin, Y. Zhang, X. Fu, and J. Lu, "Anti-inflammatory effects of ononin on lipopolysaccharide-stimulated RAW 264.7 cells," Molecular Immunology, vol. 83, pp. 46–51, 2017.

[119] S. Kaur and A. Muthuraman, "Ameliorative effect of gallic acid in paclitaxel-induced neuropathic pain in mice," Toxicology Reports, vol. 6, pp. 505–513, 2019.

[120] X. Sun, H. Zeng, Q. Wang et al., "Glycyrrhizin ameliorates inflammatory pain by inhibiting microglial activation-meiated inflammatory response via blockage of the HMGB1–TLR4–NF-κB pathway," Experimental Cell Research, vol. 369, no. 1, pp. 112–119, 2018.

[121] Y. Wang, C. Xu, P. Wang et al., "Pharmacokinetic comparisons of different combinations of shaoyao-gancao-decoction in rats: simultaneous determination of ten active constituents by HPLC-MS/MS," Journal of Chromatography B, vol. 932, pp. 76–87, 2013.

[122] C.-H. Xu, P. Wang, Y. Wang et al., "Pharmacokinetic comparisons of two different combinations of shaoyao-gancao decoction in rats: competing mechanisms between paeoniflorin and glycyrrhetinic acid," Journal of Ethnopharmacology, vol. 149, no. 2, pp. 443–452, 2013.

[123] V. G. Yerra, A. K. Kalvala, and A. Kumar, "Isoliquiritigenin reduces oxidative damage and alleviates mitochondrial impairment by SIRT1 activation in experimental diabetic neuropathy," The Journal of Nutritional Biochemistry, vol. 47, pp. 41–52, 2017.

[124] C. Yu, Y. Zhang, K.-X. Gao et al., "Serotoninergically dependent antinociceptive and antiallodynic effects of isoliquiritin in a mouse model of neuropathic pain," European Journal of Pharmacology, vol. 881, Article ID 173184, 2020.

[125] L. Zhang, D.-c. Li, and L.-f. Liu, "Paeonol: pharmacological effects and mechanisms of action," International Immunopharmacology, vol. 72, pp. 413–421, 2019.

[126] M.-T. Zhang, B. Wang, Y.-N. Jia et al., "Neuroprotective effect of liquiritin against neuropathic pain induced by chronic constriction injury of the sciatic nerve in mice," Biomedicine & Pharmacotherapy, vol. 95, pp. 186–198, 2017.

[127] J. Zhou, L. Wang, J. Wang et al., "Paeoniflorin and albiflorin attenuate neuropathic pain via MAPK pathway in chronic constriction injury rats," Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 8082753, 11 pages, 2016.

[128] S.-A. Kim, E.-S. Jang, A. Lee, S.-J. Lee, and J.-H. Kim, "Anti-inflammatory and anti-oxidant effects of oxypaeoniflorin, paeoniflorin and Paeonia lactiflora cv. ‘red charm’ flower petal extracts in macrophage cells," Korean Journal of Plant Resources, vol. 33, no. 3, pp. 153–162, 2020.

[129] D. Y. Cho, Y. A. Kim, and T. M. Przytynka, "Chapter 5: network biology approach to complex diseases," PLoS Computational Biology, vol. 8, no. 12, Article ID e1002820, 2012.

[130] H. Jeong, S. P. Mason, A.-L. Barabási, and Z. N. Oltvai, "Lethality and centrality in protein networks," Nature, vol. 411, no. 6833, pp. 41–42, 2001.

[131] J. Zhu, X. Yi, Y. Zhang, Z. Pan, L. Zhong, and P. Huang, "Systems pharmacology-based approach to comparatively study the independent and synergistic mechanisms of danhong injection and naxointong capsule in ischemic stroke treatment," Evidence-Based Complementary and Alternative Medicine, vol. 2019, Article ID 1056708, 17 pages, 2019.

[132] J. Zhong, Z. Liu, X. Zhou, and J. Xu, "Synergic anti-pruritus mechanisms of action for the radix Sophora flavescentis and fructus cnidii herbal pair," Molecules, vol. 22, no. 9, Article ID 1465, 2017.

[133] J. R. Perkins, J. Lees, A. Antunes-Martins et al., "PainNetworks: a web-based resource for the visualisation of pain-related genes in the context of their network associations," Pain, vol. 154, no. 12, pp. 2586 e1–2586.e12, 2013.

[134] T. Shi, X. Shen, and G. Gao, "Gene expression profiles of peripheral blood monocytes in osteoarthritis and analysis of differentially expressed genes," BioMed Research International, vol. 2019, Article ID 4291689, 12 pages, 2019.

[135] N. Lukkahatai, B. Majors, S. Reddy, B. Walitt, and L. N. Saligan, "Gene expression profiles of fatigue fibromyalgia patients with different categories of pain and catastrophizing: a preliminary report," Nursing Outlook, vol. 61, no. 4, pp. 216.e2–224.e2, 2013.

[136] N. Lukkahatai, B. Walitt, A. Espina, D. Wang, and L. N. Saligan, "Comparing genomic profiles of women with and without fibromyalgia," Biological Research For Nursing, vol. 17, no. 4, pp. 373–383, 2015.

[137] A. Vincent, R. P. Benzo, M. O. Whipple, S. J. McAllister, P. J. Erwin, and L. N. Saligan, "Beyond pain in fibromyalgia: insights into the symptom of fatigue," Arthritis Research & Therapy, vol. 15, no. 6, p. 221, 2013.

[138] D. S. M. Nascimento, C. S. Potes, M. L. Soares et al., "Drug-induced HSP90 inhibition alleviates pain in monoarthritic rats and alters the expression of new putative pain players at the DRG," Molecular Neurobiology, vol. 55, no. 5, pp. 3959–3975, 2018.

[139] B. Duan, D.-S. Liu, Y. Huang et al., "PI3-kinase/Akt pathway-regulated membrane insertion of acid-sensing ion channel 1a underlies BDNF-induced pain hypersensitivity," Journal of Neuroscience, vol. 39, no. 18, pp. 5631–5632, 2019.

[140] X. Guan, Q. Fu, X. Xiong et al., "Activation of PI3K/Akt pathway mediates bone cancer pain in rats," Journal of Neurochemistry, vol. 134, no. 3, pp. 590–600, 2015.

[141] X.-H. Guan, Q.-C. Fu, D. Shi et al., "Activation of spinal chemokine receptor CXCR3 mediates bone cancer pain through an Akt-ERK crosstalk pathway in rats," Experimental Neurology, vol. 263, pp. 39–49, 2015.

[142] R. P. Guedes, A. S. R. Araújo, D. Janner, A. Belló-Klein, M. F. M. Ribeiro, and W. A. Partata, "Increase in reactive oxygen species and activation of Akt signaling pathway in neuropathic pain," Cellular and Molecular Neurobiology, vol. 28, no. 8, pp. 1049–1056, 2008.

[143] B. Hu, G. Xu, X. Zhang et al., "Paeonilin attenuates inflammatory pain by inhibiting microglial activation and Akt-NF-xb signaling in the central nervous system," Cellular Physiology and Biochemistry, vol. 47, no. 2, pp. 842–850, 2018.

[144] D. Jin, J.-p. Yang, J.-h. Hu, L.-n. Wang, and J.-L. Zhao, "MCP-1 stimulates spinal microglia via PI3K/Akt pathway in bone cancer pain," Brain Research, vol. 1599, pp. 158–167, 2015.
Evidence-Based Complementary and Alternative Medicine 13

[145] C. Kersten and M. G. Cameron, “Cetuximab alleviates neuropathic pain despite tumour progression,” BMJ Case Reports, vol. 2012, Article ID bcr1220115374, 2012.

[146] C. Kersten, M. G. Cameron, B. Laird, and S. Mjåland, “Epidermal growth factor receptor—inhibition (EGFR-I) in the treatment of neuropathic pain,” British Journal of Anaesthesia, vol. 115, no. 5, pp. 761–767, 2015.

[147] D. Li, H. Chen, X.-H. Luo, Y. Sun, W. Xia, and Y.-C. Xiong, “CX3CR1-mediated Akt1 activation contributes to the paclitaxel-induced painful peripheral neuropathy in rats,” Neurochemical Research, vol. 41, no. 6, pp. 1305–1314, 2016.

[148] S.-S. Li, W.-S. Zhang, J.-L. Yang, Y.-C. Xiong, Y.-Q. Zhang, and H. Xu, “Involvement of protein kinase B/Akt in analgesic effect of dexmedetomidine on neuropathic pain,” CNS Neuroscience & Therapeutics, vol. 19, no. 5, pp. 364–366, 2013.

[149] X. Li, S. Yang, L. Wang et al., “Resveratrol inhibits paclitaxel-induced neuropathic pain by the activation of PI3K/Akt and SIRT1/PGC1alpha pathway,” Journal of Pain Research, vol. 12, pp. 879–890, 2019.

[150] W. Liu, Y. Lv, and F. Ren, “PI3K/Akt pathway is required for spinal central sensitization in neuropathic pain,” Cellular and Molecular Neurobiology, vol. 38, no. 3, pp. 747–755, 2018.

[151] L. J. Martin, S. B. Smith, A. Khoutorsky et al., “Epiregulin and EGFR interactions are involved in pain processing,” The Journal of Clinical Investigation, vol. 127, no. 9, pp. 3353–3366, 2017.

[152] N. N. Scheff, Y. Ye, Z. R. Conley et al., “A disintegrin and metalloproteinase domain 17-epidermal growth factor receptor interactions are involved in pain processing,” The Journal of Clinical Investigation, vol. 127, no. 9, pp. 3286–294, 2007.

[153] S. Wang, S. Liu, L. Xu et al., “The upregulation of EGFR in the dorsal root ganglion contributes to chronic compression of dorsal root ganglia-induced neuropathic pain in rats,” Molecular Pain, vol. 15, Article ID 1744806916644929, 2016.

[154] Y. Yan, Y. Liang, T. Ding, and H. Chu, “PI3K/Akt signaling pathway may be involved in MCP-1-induced P2X4R expression in cultured microglia and cancer-induced bone pain rats,” Neuroscience Letters, vol. 701, pp. 100–105, 2019.

[155] W. Zhang, M. Suo, G. Yu, and M. Zhang, “Antinoceptive and anti-inflammatory effects of cryptotanshinone through PI3K/Akt signaling pathway in a rat model of neuropathic pain,” Chem Biol Interact, vol. 305, pp. 127–133, 2019.

[156] M. M. Han, C. W. Yang, C. W. Cheung, and J. Li, “Blockage of spinal endothelin A receptors attenuates bone cancer pain via regulation of the Akt/ERK signaling pathway in mice,” Neuropeptides, vol. 68, pp. 36–42, 2018.

[157] R. R. Rivera, M. E. Lin, E. C. Bornhop, and J. Chun, “Conditional Lpar1 gene targeting identifies cell types mediating neuropathic pain,” Federation of American Societies for Experimental Biology Journal, vol. 34, no. 7, pp. 8833–8842, 2020.

[158] M. Srikanth, W. S. Chew, T. Hind et al., “Lysophosphatidic acid and its receptor LPA1 mediate carrageenan induced inflammatory pain in mice,” European Journal of Pharmacology, vol. 841, pp. 49–56, 2018.

[159] H. Uchida, J. Nagai, and H. Ueda, “Lysophosphatidic acid and its receptors LPA1 and LPA3 mediate paclitaxel-induced neuropathic pain in mice,” Molecular Pain, vol. 10, p. 71, 2014.

[160] H. Ueda and H. Neyama, “LPA1 receptor involvement in fibromyalgia-like pain induced by intermittent psychological stress,” Neurobiology of Pain, vol. 1, pp. 16–25, 2017.

[161] H. Ueda, H. Neyama, and Y. Matsushita, “Lysophosphatidic acid receptor 1- and 3-mediated hyperalgesia and hypoalgesia in diabetic neuropathic pain models in mice,” Cells, vol. 9, no. 8, Article ID 1906, 2020.

[162] H. Ueda, H. Neyama, K. Sasaki, C. Miyama, and R. Iwamoto, “Lysophosphatidic acid LPA1 and LPA3 receptors play roles in the maintenance of late tissue plasminogen activator-induced central poststroke pain in mice,” Neurobiol Pain, vol. 5, Article ID 100020, 2019.

[163] J. X. Wu, X. M. Yuan, Q. Wang, W. Wei, and M. Y. Xu, ”Rho/ROCK acts downstream of lysophosphatidic acid receptor 1 in modulating P2X3 receptor-mediated bone cancer pain in rats,” Molecular Pain, vol. 12, Article ID 1744806916644929, 2016.

[164] X. P. Wu, Y. P. Yang, R. X. She, Z. M. Xing, H. W. Chen, and Y. W. Zhang, “microRNA-329 reduces bone cancer pain through the LPAR1-dependent LPAR1/ERK signal transduction pathway in mice,” Therapeutic Advances in Medical Oncology, vol. 11, Article ID 175885919875319, 2019.

[165] L. Ma, H. Uchida, J. Nagai et al., “Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain,” Molecular Pain, vol. 5, p. 64, 2009.

[166] M. Wei, L. Li, Y. Zhang, M. Zhang, and Z. Su, “Downregulated circular RNA zRANB1 mediates Wnt5a/beta-Catenin signaling to promote neuropathic pain via miR-24-3p/LPAR3 axis in CCI rat models,” Gene, vol. 761, Article ID 145038, 2020.

[167] S. J. Yue, J. Liu, W. W. Feng et al., “System pharmacology-based dissection of the synergistic mechanism of huangqi and huanglian for diabetes mellitus,” Frontiers in Pharmacology, vol. 8, p. 694, 2017.

[168] C. M. Chen, W. L. Chen, C. T. Hung et al., “Shaoyao Gancao Tang (SG-Tang), a formulated Chinese medicine, reduces aggregation and exerts neuroprotection in spinocerebellar ataxia type 17 (SCA17) cell and mouse models,” Aging (Albany NY), vol. 11, no. 3, pp. 986–1007, 2019.

[169] S. J. Jeong, H. S. Lim, C. S.seo et al., “Traditional herbal formula Jakyakgamcho-tang (Paonia lactiflora and Glycyrrhiza uralensis) impairs inflammatory chemokine production by inhibiting activation of STAT1 and NF-kB in HaCaT cells,” Phytomedicine, vol. 22, no. 2, pp. 326–332, 2015.

[170] T. H. Kang, H. Y. Baek, and Y. C. Kim, “Protective effect of jakyak-gamcho-tang extract and its constituents against t-BHP-induced oxidative damage in HT22 cells,” The American Journal of Chinese Medicine, vol. 33, no. 2, pp. 181–189, 2005.

[171] T. Maeda, K. Shinozuka, K. Baba, M. Hayashi, and E. Hayashi, “Effect of shakuyaku-kanzoh-toh, a prescription composed of shakuyaku (Paeoniae Radix) and kanzoh (Paeonia lactiflora) formula Jakyakgamcho-tang on Guinea pig ileum,” J Pharmacobiodyn, vol. 6, no. 3, pp. 153–160, 1983.

[172] S. P. Cohen and J. Mao, “Neuropathic pain: mechanisms and their clinical implications,” BMJ, vol. 348, Article ID f7656, 2014.

[173] J. Gierthmühlen and R. Baron, “Neuropathic pain,” Seminars in Neurology, vol. 36, no. 5, pp. 462–468, 2016.
Evidence-Based Complementary and Alternative Medicine

[175] S. Heinzmann and S. B. McMahon, “New molecules for the treatment of pain,” Current Opinion in Supportive and Palliative Care, vol. 5, no. 2, pp. 111–115, 2011.

[176] J. Huang, X. Zhang, and P. A. McNaughton, “Inflammatory pain: the cellular basis of heat hyperalgesia,” Current Neuropharmacology, vol. 4, no. 3, pp. 197–206, 2006.

[177] M. Inoue, M. H. Rashid, R. Fujita, J. J. Contos, J. Chun, and H. Ueda, “Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling,” Nature Medicine, vol. 10, no. 7, pp. 712–718, 2004.

[178] R. R. Ji and G. Strichartz, “Cell signaling and the genesis of neuropathic pain,” Science’s STKE, vol. 252, Article ID reE14, 2004.

[179] R. R. Ji, Z. Z. Xu, and Y. J. Gao, “Emerging targets in neuropathic pain,” J. Cui, W. He, B. Yi et al., “mTOR pathway is involved in the regulation of pain in rats,” Pain, vol. 156, no. 6, pp. 1124–1144, 2015.

[180] S. Pezet, F. Marchand, R. D’Mello et al., “PI3K/Akt pathway: a potential therapeutic target for chronic pain,” Nature Reviews Drug Discovery, vol. 2, no. 6, pp. 460–472, 2003.

[181] T. J. Price, A. I. Basbaum, J. Bresnahan et al., “Transition to spinal dorsal horn in a rat neuropathic pain model,” Pain Reports, vol. 275, no. 1, pp. 395–403, 2016.

[182] R. Raoof, H. Willemen, and N. Eijkelkamp, “Divergent roles of immune cells and their mediators in pain,” Rheumatology (Oxford), vol. 57, no. 3, pp. 429–440, 2018.

[183] D. W. Sah, M. H. Ossipo, and F. Porreca, “Neurotrophic factors as novel therapeutics for neuropathic pain,” Nature Reviews Drug discovery, vol. 10, no. 12, pp. 694–707, 2014.

[184] F. A. White, S. K. Bhangoo, and R. J. Miller, “Chemokines: integrators of pain and inflammation,” Nature Reviews Drug Discovery, vol. 4, no. 10, pp. 834–844, 2005.

[185] M. Calvo, N. Zhu, C. Tsantoulas et al., “Regulatin-GerB signaling promotes microglial proliferation and chemotaxis contributing to microgliosis and pain after peripheral nerve injury,” The Journal of Neuroscience, vol. 35, no. 4, pp. 735–739, 2017.

[186] M. Sisignano, R. Baron, K. Scholich, and G. Geisslinger, “Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain,” Nature Reviews Neurology, vol. 10, no. 12, pp. 694–707, 2014.

[187] Y. D. Liu, Z. B. Wang, G. Han, L. Jin, and P. Zhao, “Hyperbaric oxygen promotes mitophagy by activating the mTOR pathway,” Journal of Pain Research, vol. 13, no. 7, pp. 712–718, 2019.

[188] Y. Gui, A. Li, F. Chen et al., “Involvement of AMPK/SIRT1 pathway in anti-allodynic effect of troxerutin in CCI-induced neuropathic pain,” European Journal of Pharmacology, vol. 769, pp. 234–241, 2015.

[189] S. Hao, M. Mata, J. C. Glorioso, and D. J. Fink, “Gene transfer to interfere with TNFα signaling in neuropathic pain,” Gene Therapy, vol. 14, no. 13, pp. 1010–1016, 2007.

[190] J. Huang, D. Chen, F. Yan et al., “TTC-801 alleviates mechanical allodynia in paclitaxel-induced neuropathic pain through the P38/PI3K/Akt pathway,” European Journal of Pharmacology, vol. 883, Article ID 173306, 2020.

[191] S. Pezet, F. Marchand, R. D’Mello et al., “PI3K/Akt pathway: a potential therapeutic target for chronic pain,” Nature Reviews Drug Discovery, vol. 2, no. 6, pp. 460–472, 2003.

[192] Y. D. Liu, Z. B. Wang, G. Han, L. Jin, and P. Zhao, “Hyperbaric oxygen relieves neuropathic pain through AKT/TSC2/mTOR pathway activity to induce autophagy,” Journal of Pain Research, vol. 12, pp. 443–451, 2019.

[193] Y. D. Liu, Z. B. Wang, G. Han, and P. Zhao, “Hyperbaric oxygen treatment attenuates neuropathic pain by elevating autophagy flux via inhibiting mTOR pathway,” American Journal of Translational Research, vol. 9, no. 5, pp. 2629–2638, 2017.

[194] Y. Lu, B. C. Jiang, D. L. Cao et al., “TRAF6 upregulation in spinal astrocytes maintains neuropathic pain by integrating TNF-alpha and IL-1β signaling,” Pain, vol. 155, no. 12, pp. 2618–2629, 2014.

[195] D. W. Sah, M. H. Ossipo, and F. Porreca, “Neurotrophic factors as novel therapeutics for neuropathic pain,” Nature Reviews Drug discovery, vol. 10, no. 12, pp. 694–707, 2014.

[196] J. Cui, W. He, B. Yi et al., “mTOR pathway is involved in ADP-evoked astrocyte activation and ATP release in the spinal dorsal horn in a rat neuropathic pain model,” Neuroscience, vol. 275, pp. 395–403, 2014.

[197] H. H. Ding, S. B. Zhang, Y. Y. Lv et al., “TNF-alpha/STAT3 pathway epigenetically upregulates Nav1.6 expression in DRG and contributes to neuropathic pain induced by L5-VTR,” Journal of Neuroinflammation, vol. 16, no. 1, p. 29, 2019.

[198] Y. D. Liu, Z. B. Wang, G. Han, and P. Zhao, “Hyperbaric oxygen treatment attenuates neuropathic pain by elevating autophagy flux via inhibiting mTOR pathway,” American Journal of Translational Research, vol. 9, no. 5, pp. 2629–2638, 2017.

[199] Y. Lu, B. C. Jiang, D. L. Cao et al., “TRAF6 upregulation in spinal astrocytes maintains neuropathic pain by integrating TNF-alpha and IL-1β signaling,” Pain, vol. 155, no. 12, pp. 2618–2629, 2014.

[200] D. W. Maixner, X. Yan, M. Gao, R. Yadav, and H. R. Weng, “Adenosine monophosphate-activated protein kinase regulates interleukin-1β expression and glial glutamate transporter function in rodents with neuropathic pain,” Anesthesiology, vol. 122, no. 6, pp. 1401–1413, 2015.

[201] G. L. Mejia, M. N. Asiedu, Y. Hitoshi, G. Dussor, and T. J. Price, “The potent, indirect adenosine monophosphate-activated protein kinase activator R419 attenuates mitogen-activated protein kinase signaling, inhibits nociceptor excitability, and reduces pain hypersensitivity in mice,” Pain Reports, vol. 1, no. 1, Article ID e562, 2016.

[202] I. Obara, K. K. Tochiki, S. M. Geranton et al., “Systemic inhibition of the mammalian target of rapamycin (mTOR) signaling pathway,” Translational Neuroscience, vol. 10, pp. 175–179, 2019.
pathway reduces neuropathic pain in mice,” Pain, vol. 152, no. 11, pp. 2582–2595, 2011.

[207] T. J. Price, V. Das, and G. Dussor, “Adenosine monophosphate-activated protein kinase (AMPK) activators for the prevention, treatment and potential reversal of pathological pain,” Current Drug Targets, vol. 17, no. 8, pp. 908–920, 2016.

[208] I. Sabsovich, T. Z. Guo, T. Wei et al., "TNF signaling contributes to the development of nociceptive sensitization in a tibia fracture model of complex regional pain syndrome type I." Pain, vol. 137, no. 3, pp. 307–319, 2008.

[209] J. Shi, K. Jiang, and Z. Li, “MiR-145 ameliorates neuropathic pain via inhibiting inflammatory responses and mTOR signaling pathway by targeting Akt3 in a rat model," Neuroscience Research, vol. 134, pp. 10–17, 2018.

[210] M. Sobeh, M. F. Mahmoud, S. Rezq et al., "Salix tetrasperma rootb. Extract alleviates neuropathic pain in rats via modulation of the NF-kB/TNF-a/NOX/NOS pathway," Antioxidants (Basel), vol. 8, no. 10, p. 482, 2019.

[211] H. Song, Y. Han, C. Pan et al., “Activation of adenosine monophosphate-activated protein kinase suppresses neuroinflammation and ameliorates bone cancer pain: involvement of inhibition on mitogen-activated protein kinase,” Anesthesiology, vol. 123, no. 5, pp. 1170–1185, 2015.

[212] F. Tao, Q. Li, S. Liu et al., “Role of neuregulin-1/ErbB signaling in stem cell therapy for spinal cord injury-induced chronic neuropathic pain,” Stem Cells, vol. 31, no. 1, pp. 83–91, 2013.

[213] R. Wang, Z. Qiu, G. Wang et al., “Quercetin attenuates diabetic neuropathic pain by inhibiting mTOR/p70S6K pathway-mediated changes of synaptic morphology and synaptic protein levels in spinal dorsal horn of db/db mice," European Journal of Pharmacology, vol. 882, Article ID 173266, 2020.

[214] X. Xie, L. Ma, K. Xi, W. Zhang, and D. Fan, “MicroRNA-183 suppresses neuropathic pain and expression of AMPA receptors by targeting mTOR/VEGF signaling pathway,” Cell Physiol Biochem, vol. 41, no. 1, pp. 181–192, 2017.

[215] X. Xing, K. Wu, Y. Dong et al., “Hyperactive Akt-mTOR pathway as a therapeutic target for pain hypersensitivity in Cntnap2-deficient mice," Neuropharmacology, vol. 165, Article ID 107816, 2020.

[216] G. Yang, Q. Tan, Z. Li et al., “The AMPK pathway triggers autophagy during CSF1-induced microglial activation and may be implicated in inducing neuropathic pain,” Journal of Neuroimmunology, vol. 345, Article ID 577261, 2020.

[217] Q. Q. Yang, H. N. Li, S. T. Zhang et al., “Red nucleus IL-6 mediates the maintenance of neuropathic pain by inducing the productions of TNF-α and IL-1β through the JAK2/STAT3 and ERK signaling pathways," Neuropathology, vol. 40, no. 4, 2020.

[218] L. Yuan, C. Liu, Y. Wan, H. Yan, and T. Li, “Effect of HDAC2/Inpp5f on neuropathic pain and cognitive function through regulating PI3K/Akt/GSK-3β signal pathway in rats with neuropathic pain," Experimental and Therapeutic Medicine, vol. 18, no. 1, pp. 678–684, 2019.

[219] J. Zhang, L. Wang, H. Wang, Z. Su, and X. Pang, “Neuroinflammation and central PI3K/Akt/mTOR signal pathway contribute to bone cancer pain," Molecular Pain, vol. 15, Article ID 1744806918032040, 2019.

[220] Q. Zhang, J. Yu, J. Wang et al., “The red nucleus TNF-alpha participates in the initiation and maintenance of neuropathic pain through different signaling pathways," Neurochemical Research, vol. 40, no. 7, pp. 1360–1371, 2015.

[221] W. Zhang, X. Bai, Y. Qiao et al., "8-O-acetyl shanzhiside methylster from lamphomis rotata reduces neuropathic pain by inhibiting the ERK/TNF-alpha pathway in spinal astrocytes," Frontiers in Cellular Neuroscience, vol. 12, p. 54, 2018.

[222] Y. Zhang, L. Yuan, Y. Chen, C. Lin, and G. Ye, "Oxyntomodulin attenuates TNFα induced neuropathic pain by inhibiting the activation of the NFκB pathway," Molecular Medicine Reports, vol. 20, no. 6, pp. 5223–5228, 2019.

[223] Z. Zhang, M. Deng, J. Huang et al., “Microglial annexin A3 downregulation alleviates bone cancer-induced pain via inhibiting the Hif-1alpha/VEGF signaling pathway," Pain, vol. 161, no. 12, pp. 2750–2762, 2020.

[224] D. Zhao, D. F. Han, S. S. Wang, B. Ly, X. Wang, and C. Ma, “Roles of tumor necrosis factor-alpha and interleukin-6 in regulating bone cancer pain via TRPA1 signal pathway and beneficial effects of inhibition of neuro-inflammation and TRPA1," Molecular Pain, vol. 15, Article ID 1744806918057981, 2019.

[225] A. Jia and M. Zhu, “Effects of curcumin on behavioral and NF-kB/TNF-a pathway in mice with metastatic bone pain of breast cancer induced by walker 256 cells," Cancer Ther, vol. 11, no. 6, p. 339, 2020.

[226] S. Dehghani, E. Alijopour, A. Salimzedeh et al., “The effect of a garlic supplement on the pro-inflammatory adipokine, resistin and tumor necrosis factor-alpha, and on pain severity, in overweight or obese women with knee osteoarthritis," Phytomedicine, vol. 48, pp. 70–75, 2018.

[227] Y. Tian, S. Wang, Y. Ma, G. Lim, H. Kim, and J. Mao, “Leptin enhances NMDA-induced spinal excitation in rats: a functional link between adipocytokine and neuropathic pain," Pain, vol. 152, no. 6, pp. 1263–1271, 2011.

[228] R. Ji, Z. Zhuang, H. Xu, and D. J. T. J. o.P. Clapham, “Phosphatidylinositol 3-kinase (PI3K) cascade is a novel signaling pathway to mediate inflammatory pain," Journal of Pain, vol. 6, no. 3, Article ID S11, 2005.

[229] Y. Ji, B. Tang, and R. J. Traub, “Spinal estrogen receptor alpha mediates estradiol-induced pronociception in a visceral pain model in the rat," Pain, vol. 152, no. 5, pp. 1182–1191, 2011.

[230] V. Khariv, C. Acioglu, L. Ni et al., “A link between plasma membrane calcium ATPase 2 (PMCA2), estrogen and estrogen receptor alpha signaling in mechanical pain," Scientific Reports, vol. 8, no. 1, Article ID 17260, 2018.

[231] F. Piu, C. Cheevers, L. Hyldtoft et al., "Broad modulation of neuropathic pain states by a selective estrogen receptor beta agonist," European Journal of Pharmacology, vol. 590, no. 1–3, pp. 423–429, 2008.

[232] B. Tang, Y. Ji, and R. J. Traub, “Estrogen alters spinal NMDA receptor activity via a PKA signaling pathway in a visceral pain model in the rat," Pain, vol. 137, no. 3, pp. 540–549, 2008.

[233] X. L. Yan, C. C. Feng, Q. Liu et al., “Vagal afferents mediate antinociception of estrogen in a rat model of visceral pain: the involvement of intestinal mucosal mast cells and 5-hydroxytryptamine 3 signaling," The Journal of Pain, vol. 15, no. 2, pp. 204–217, 2014.

[234] M. Zielinska, J. Fichna, M. Bashashati et al., “G protein-coupled estrogen receptor and estrogen receptor ligands regulate colonic motility and visceral pain,"
Evidence-Based Complementary and Alternative Medicine

Neurogastroenterology & Motility, vol. 29, no. 7, Article ID e13025, 2017.

M. Busch-Dienstfertig and S. Gonzalez-Rodriguez, “IL-4, JAK-STAT signaling, and pain,” JAKSTAT; vol. 2, no. 4, Article ID e27638, 2013.

S. Cao, Y. Li, L. Wang et al., “Synergistic analgesic effect of propofol-alfentanil combination through detecting the inhibition of cAMP signal pathway,” Journal of Pharmacy and Pharmacology, vol. 68, no. 9, pp. 1170–1176, 2016.

S. P. Chen, J. Sun, Y. Q. Zhou et al., “Sinomenine attenuates cancer-induced bone pain via suppressing microglial JAK2/STAT3 and neuronal CAMKII/CREB cascades in rat models,” Molecular Pain, vol. 14, Article ID 1744086918793232, 2018.

L. H. Hang, J. P. Yang, D. H. Shao, Z. Chen, and H. Wang, “Involvement of spinal PKA/CREB signaling pathway in the development of bone cancer pain,” Pharmacological Reports, vol. 65, no. 3, pp. 710–716, 2013.

H. T. Hsiao, Y. C. Lin, J. C. Wang, Y. C. Tsai, and Y. C. Liu, “Hypoxia inducible factor-1α induction produced anti-allodynia effect and suppressed inflammatory cytokine production in early stage of mouse complex regional pain syndrome model,” Clinical and Experimental Pharmacology and Physiology, vol. 43, no. 3, pp. 355–359, 2016.

H. T. Hsiao, Y. Y. Liu, J. C. Wang, Y. C. Lin, and Y. C. Liu, “The analgesic effect of propofol associated with the inhibition of hypoxia inducible factor and inflamasome in complex regional pain syndrome,” Journal of Biomedical Science, vol. 26, no. 1, p. 74, 2019.

Y. L. Hsieh, L. W. Chou, P. L. Chang, C. C. Yang, M. J. Kao, and C. Z. Hong, “Low-level laser therapy alleviates neuropathic pain and promotes function recovery in rats with chronic constriction injury: possible involvements in hypoxia-inducible factor I alpha (HIF-1α),” The Journal of Comparative Neurology, vol. 520, no. 13, pp. 2903–2916, 2012.

W. Kallenborn-Gerhardt, K. Metzner, R. Lu et al., “Neuropathic and cAMP-induced pain behavior is ameliorated in mice lacking CNGB1,” Neuropharmacology, vol. 171, Article ID 108087, 2020.

K. M. Kober, M. C. Lee, A. Olshen et al., “Differential methylation and expression of genes in the hypoxia-inducible factor 1 signaling pathway are associated with pachytaxel-induced peripheral neuropathy in breast cancer survivors and with preclinical models of chemotherapy-induced neuropathic pain,” Molecular Pain, vol. 16, Article ID 1744086920936502, 2020.

J. T. Liou, F. C. Liu, S. T. Hsin, C. Y. Yang, and P. W. Lui, “Inhibition of the cyclic adenosine monophosphate pathway attenuates neuropathic pain and reduces phosphorylation of cyclic adenosine monophosphate response element-binding in the spinal cord after partial sciatic nerve ligation in rats,” Anesthesia & Analgesia, vol. 105, no. 6, pp. 1830–1837, 2007.

T. Ludman and O. K. Melemedjian, “Bortezomib and metformin opposingly regulate the expression of hypoxia-inducible factor alpha and the consequent development of chemotherapy-induced painful peripheral neuropathy,” Molecular Pain, vol. 15, Article ID 1744086918793232, 2019.

D. R. Rojas, I. Tegeder, R. Kuner, and N. Agarwal, “Hypoxia-inducible factor I alpha protects peripheral sensory neurons from diabetic peripheral neuropathy by suppressing accumulation of reactive oxygen species,” Journal of Molecular Medicine, vol. 96, no. 12, pp. 1395–1405, 2018.

F. Salaffi, G. Giacobazzi, and M. Di Carlo, “Chronic pain in inflammatory arthritis: mechanisms, metrology, and emerging targets-A focus on the JAK-STAT pathway,” Pain Research and Management, vol. 2018, Article ID 8564215, 14 pages, 2018.

F. Salehi, M. S. Hosseini-Zare, H. Aghajani, S. Y. Seyed, M. S. Hosseini-Zare, and M. Sharifzadeh, “Effect of bunchesine, pentoxifylline, and H-89 as cyclic adenosine monophosphate analog, phosphodiesterase, and protein kinase A inhibitor on acute pain,” Fundamental & Clinical Pharmacology, vol. 31, no. 4, pp. 411–419, 2017.

X. M. Shao, J. Sun, Y. L. Ji, Wang et al., “Inhibition of the cAMP/PKA/CREB pathway contributes to the analgesic effects of electroacupuncture in the anterior cingulate cortex in a rat pain memory model,” Neural Plasticity, vol. 2016, Article ID 5320641, 16 pages, 2016.

J. Tang, Z. H. Li, S. N. Ge et al., “The inhibition of spinal astrocytic JAK2-STAT3 pathway activation correlates with the analgesic effects of triptolide in the rat neuropathic pain model,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 185167, 13 pages, 2012.

H. Wang, X. Huo, H. Chen et al., “Hydrogen-rich saline activated autophagy via HIF-1alpha pathways in neuropathic pain model,” BioMed Research International, vol. 2018, Article ID 4670834, 2018.

Z. Xiong, J. Ding, J. Zhou, S. Yao, J. Zheng, and X. Guo, “Correlation between the HIF-1α/Notch signaling pathway and Modic changes in nucleus pulposus cells isolated from patients with low back pain,” BMC Musculoskeletal Disorders, vol. 21, no. 1, p. 500, 2020.

S. Xu and R. Zheng, “Dexmedetomidine alleviates neuropathic pain by regulating JAK/STAT pathway in rats,” Journal of Cellular Biochemistry, vol. 121, no. 3, pp. 2277–2283, 2020.

G. Zhang, G. Y. Feng, Y. R. Guo, D. Q. Liang, Y. Yuan, and H. L. Wang, “Correlation between liver cancer pain and the HIF-1 and VEGF expression levels,” Oncology Letters, vol. 13, no. 1, pp. 77–80, 2017.

G. Q. Zhu, S. Liu, D. D. He, Y. P. Liu, and X. J. Song, “Activation of the cAMP-PKA signaling pathway in rat dorsal root ganglion and spinal cord contributes toward induction and maintenance of bone cancer pain,” Behavioural Pharmacology, vol. 25, no. 4, pp. 267–276, 2014.

D. A. Skyba, R. Radhakrishnan, M. K. H. Bement, and K. A. Sluka, “The CAMP pathway and pain: potential targets for drug development,” Drug Discovery Today: Disease Models, vol. 1, no. 2, pp. 115–119, 2004.

V. P. Androutsopoulos, K. Ruparelia, R. R. Arroo, A. M. Tsatsakis, and D. A. Spandidos, “CYP1-mediated antiproliferative activity of dietary flavonoids in MDA-MB-468 breast cancer cells,” Toxicology, vol. 264, no. 3, pp. 162–170, 2009.

M. V. Chao, R. Rajagopal, and F. S. Lee, “Neurotrophin signalling in health and disease,” Clinical Science (London), vol. 110, no. 2, pp. 167–173, 2006.

X. M. Hu, H. Zhang, H. Xu et al., “Chemokine receptor CXCR4 regulates CaMKII/CREB pathway in spinal neurons that underlies cancer-induced bone pain,” Scientific Reports, vol. 7, no. 1, Article ID 4005, 2017.

N. Khan and M. T. Smith, “Neurotrophins and neuropathic pain: role in pathobiology,” Molecules, vol. 20, no. 6, pp. 10657–10688, 2015.

R. J. Mannion, M. Costigan, I. Decosterd et al., “Neurotrophins: periodically and centrally acting modulators of tactile stimulus-induced inflammatory pain hypersensitivity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 48, pp. 19689–19694, 2012.
Evidence-Based Complementary and Alternative Medicine

United States of America, vol. 96, no. 16, pp. 9385–9390, 1999.

[263] S. Pezet and S. B. McMahon, “Neurotrophins: mediators and modulators of pain,” Annual Review of Neuroscience, vol. 29, pp. 507–538, 2006.

[264] H. Xu, C. Peng, X. T. Chen et al., “Chemokine receptor CXCR5 activates the RhoA/ROCK2 pathway in spinal neurons that induces bone cancer pain,” Molecular Pain, vol. 16, Article ID 1744809620915658, 2020.

[265] Q. Zhang, D. L. Cao, Z. J. Zhang, B. C. Jiang, and Y. J. Gao, “Chemokine CXCL13 mediates orofacial neuropathic pain via CXCR5/ERK pathway in the trigeminal ganglion of mice,” Journal of Neuroinflammation, vol. 13, no. 1, p. 183, 2016.

[266] V. Brussee, F. A. Cunningham, and D. W. Zachodne, “Direct insulin signaling of neurons reverses diabetic neuropathy,” Diabetes, vol. 53, no. 7, pp. 1824–1830, 2004.

[267] M. Dobretsov, A. H. Ghaleb, D. Romanovsky, C. S. Pablo, and J. R. Stimers, “Impaired insulin signaling as a potential trigger of pain in diabetes and prediabetes,” International Anesthesiology Clinics, vol. 45, no. 2, pp. 95–105, 2007.

[268] S. Sharma, K. Chopra, and S. K. Kulkarni, “Effect of insulin and its combination with resveratrol or curcumin in attenuation of diabetic neuropathic pain: participation of nitric oxide and TNF-alpha,” Phytotherapy Research, vol. 21, no. 3, pp. 279–283, 2007.

[269] K. Sugimoto, I. B. Rashid, M. Shojo, T. Suda, and M. Yasujima, “Early changes in insulin receptor signaling and pain sensation in streptozotocin-induced diabetic neuropathy in rats,” The Journal of Pain, vol. 9, no. 3, pp. 237–245, 2008.

[270] E. S. Banimostafavi, M. Fakhar, S. Abediankenari et al., “Determining serum levels of IL-10 and IL-17 in patients with low back pain caused by lumbar disc degeneration,” Infectious Disorders Drug Targets, 2020.

[271] Y. J. Day, J. T. Liou, C. M. Lee et al., “Lack of interleukin-17 leads to a modulated micro-environment and amelioration of mechanical hypersensitivity after peripheral nerve injury in mice,” Pain, vol. 155, no. 7, pp. 1293–1302, 2014.

[272] X. Hu, F. Huang, and Z. J. Wang, “CaMKIIalpha mediates the effect of IL-17 to promote ongoing spontaneous and evoked pain in multiple sclerosis,” The Journal of Neuroscience, vol. 38, no. 1, pp. 232–244, 2018.

[273] C. F. Kim and G. Moalem-Taylor, “Interleukin-17 contributes to neuroinflammation and neuropathic pain following peripheral nerve injury in mice,” The Journal of Pain, vol. 12, no. 3, pp. 370–383, 2011.

[274] X. Liu, S. Fan, M. Zheng, J. Chen, I. Zhang, and H. Li, “The mediation of interleukin-17 and chemokine ligand 2 in pelvic pain of experimental autoimmune prostatitis,” Experimental and Therapeutic Medicine, vol. 14, no. 1, pp. 51–58, 2017.

[275] H. Luo, H. Z. Liu, W. W. Zhang et al., “Interleukin-17 regulates neuron-glial communications, synaptic transmission, and neuropathic pain after chemotherapy,” Cell Reports, vol. 29, no. 8, pp. 2384.e5–2397.e5, 2019.

[276] X. Meng, Y. Zhang, I. L. Lao et al., “Spinal interleukin-17 promotes thermal hyperalgesia and NMDA NR1 phosphorylation in an inflammatory pain rat model,” Pain, vol. 154, no. 2, pp. 294–305, 2013.

[277] N. Noma, J. Khan, I. F. Chen et al., “Interleukin-17 levels in rat models of nerve damage and neuropathic pain,” Neuroscience Letters, vol. 493, no. 3, pp. 86–91, 2011.

[278] F. Richter, G. Natura, M. Ebbinghaus et al., “Interleukin-17 sensitizes joint nociceptors to mechanical stimuli and contributes to arthritis pain through neuronal interleukin-17 receptors in rodents,” Arthritis & Rheumatology, vol. 64, no. 12, pp. 4125–4134, 2012.

[279] C. Sun, J. Zhang, L. Chen et al., “IL-17 contributed to the neuropathic pain following peripheral nerve injury by promoting astrocyte proliferation and secretion of proinflammatory cytokines,” Molecular Medicine Reports, vol. 15, no. 1, pp. 89–96, 2017.

[280] C. Y. Yao, Z. L. Weng, J. C. Zhang, T. Feng, Y. Lin, and S. Yao, “Interleukin-17A acts to maintain neuropathic pain through activation of CaMKII/CREB signaling in spinal neurons,” Molecular Neurobiology, vol. 53, no. 6, pp. 3914–3926, 2016.

[281] W. Zhang, L. Nie, Y. J. Guo et al., “Th17 cell frequency and IL-17 concentration correlate with pre- and postoperative pain sensation in patients with intervertebral disk degeneration,” Orthopedics, vol. 37, no. 7, pp. e685–e691, 2014.

[282] D. Zou, K. Zhang, Y. Yang et al., “Th17 and IL-17 exhibit higher levels in osteonecrosis of the femoral head and have a positive correlation with severity of pain,” Endokrynologia Polska, vol. 69, no. 3, pp. 283–290, 2018.

[283] C. Biegsmayer, G. Hofer, C. Kaiser, A. Reinthaller, B. Kopp, and H. Janisch, “Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives,” Gynecological Endocrinology, vol. 9, no. 4, pp. 307–312, 1995.

[284] C. Siming, B. Watzer, L. De Petrocellis, V. Di Marzo, and P. Imming, “Dopamides, vanillylamides, ethanolamides, and arachidonic acid amides of anti-inflammatory and analgesic drug substances as TRPV1 ligands,” ChemMedChem, vol. 3, no. 12, pp. 1956–1964, 2008.

[285] H. S. Smith, “Arachidonic acid pathways in nociception,” The Journal of Supportive Oncology, vol. 4, no. 6, pp. 277–287, 2006.

[286] B. Sung, S. Wang, B. Zhou et al., “Altered spinal arachidonic acid turnover after peripheral nerve injury regulates regional glutamate concentration and neuropathic pain behaviors in rats,” Pain, vol. 131, no. 1-2, pp. 121–131, 2007.

[287] W. Yang, R. E. Yaggie, A. J. Schaeffer, and D. J. Klumpp, “AOAH remodels arachidonic acid-containing phospholipid pools in a model of interstitial cystitis pain: a MAPP network study,” PLoS One, vol. 15, no. 9, Article ID e0235384, 2020.

[288] X. Wang, T. Wu, Y. Lee, R. J. C. P. Dionne, and A. Therapeutics, “Gene expression in the arachidonic acid pathway due to tissue injury and inflammation, an NSAID, and COXIB in a clinical model of pain,” Clinical Pharmacology & Therapeutics, vol. 77, no. 2, p. 288, 2005.

[289] D. J. Haleem, S. Nawaz, and T. Salman, “Dopamine and serotonin metabolism associated with morphine reward and its inhibition with buspirone: a study in the rat striatum,” Pharmacology Biochemistry and Behavior, vol. 170, pp. 71–78, 2018.

[290] N. Li, C. Li, R. Han et al., “LPM580098, a novel triple reuptake inhibitor of serotonin, noradrenaline, and dopamine, attenuates neuropathic pain,” Frontiers in Pharmacology, vol. 10, p. 53, 2019.

[291] I. K. Martikainen, N. Hagelberg, S. K. Jaaskelainen, J. Hietala, and A. Pertovaara, “Dopaminergic and serotonergic mechanisms in the modulation of pain: in vivo studies in human brain,” European Journal of Pharmacology, vol. 834, pp. 337–345, 2018.
[292] C. Sagheddu, S. Aroni, M. De Felice et al., "Enhanced serotonin and mesolimbic dopamine transmissions in a rat model of neuropathic pain," *Neuropharmacology*, vol. 97, pp. 383–393, 2015.

[293] L. Li, H. Qiu, M. Liu, and Y. Cai, "A network pharmacology-based study of the molecular mechanisms of shaoyao-gancao decoction in treating Parkinson’s disease," *Interdisciplinary Sciences: Chemistry*, vol. 12, no. 2, pp. 131–144, 2020.

[294] N. Zhu, J. Hou, G. Ma, and J. Liu, "Network pharmacology identifies the mechanisms of action of shaoyao gancao decoction in the treatment of osteoarthritis," *Medical Science Monitor*, vol. 25, pp. 6051–6073, 2019.

[295] V. Addepalli and S. V. Suryavanshi, "Catechin attenuates diabetic autonomic neuropathy in streptozotocin induced diabetic rats," *Biomedicine & Pharmacotherapy*, vol. 108, pp. 1517–1523, 2018.

[296] M. Deciga-Campos, R. Mata, and I. Rivero-Cruz, "Antinociceptive pharmacological profile of dysphania graveolens in mouse," *Biomedicine & Pharmacotherapy*, vol. 89, pp. 933–938, 2017.

[297] S. Islam, M. S. Shaibj, R. B. Rashid et al., "Antinociceptive activities of Artocarpus lacucha Buch-ham (Moraceae) and its isolated phenolic compound, catechin, in mice," *BMC Complementary and Alternative Medicine*, vol. 19, no. 1, p. 214, 2019.

[298] Y. Zhang, D. Sun, Q. Meng, W. Guo, Q. Chen, and Y. Zhang, "Calcium channels contribute to albiflorin-mediated antinociceptive effects in mouse model," *Neuroscience Letters*, vol. 628, pp. 105–109, 2016.

[299] R. Lima Cavendish, J. de Souza Santos, R. Belo Neto et al., "Antinociceptive and anti-inflammatory effects of Brazilian red propolis extract and formononetin in rodents," *Journal of Ethnopharmacology*, vol. 173, pp. 127–133, 2015.

[300] A. Parlar, S. O. Arslan, and S. A. Cam, "Glabridin alleviates inflammation and nociception in rodents by activating BKCa channels and reducing NO levels," *Biological and Pharmaceutical Bulletin*, vol. 43, no. 5, pp. 884–897, 2020.

[301] H. L. Wang, Y. X. Li, Y. T. Niu et al., "Observing anti-inflammatorv and anti-nociceptive activities of glycyrrhizin through regulating COX-2 and pro-inflammatory cytokines expressions in mice," *Inflammation*, vol. 38, no. 6, pp. 2269–2278, 2015.

[302] X. S. Wang, S. Y. Guan, A. Liu et al., "Anxiolytic effects of formononetin in an inflammatory pain mouse model," *Mol Brain*, vol. 12, no. 1, p. 36, 2019.

[303] Y. Farhood, A. Sarkaki, S. Hashemi, M. T. Mansouri, and M. Dianat, "The effects of gallic acid on pain and memory following transient global ischemia/reperfusion in Wistar rats," *Aviceena Journal of Phytomedicine*, vol. 3, no. 4, pp. 329–340, 2013.

[304] M. Hajimoradi, M. Farzili, M. K. Ghabir-Naseri, and A. Sarkaki, "Gallic acid and exercise training improve motor function, nerve conduction velocity but not pain sense reflex after experimental sciatic nerve crush in male rats," *Aviceena Journal of Phytomedicine*, vol. 5, no. 4, pp. 288–297, 2015.

[305] P. Feldman, M. R. Due, M. S. Ripsch, R. Khanna, and F. A. White, "The persistent release of HMGB1 contributes to tactile hyperalgesia in a rodent model of neuropathic pain," *Journal of Neuroinflammation*, vol. 9, Article ID 180, 2012.

[306] C. S. Wang, S. Y. Guan, A. Liu et al., "Anxiolytic effects of naringenin in rats with spinal nerve ligation-induced neuropathic pain," *Biomedical Reports*, vol. 2, no. 4, pp. 569–573, 2014.

[307] M. F. Manchope, C. Calixto-Campos, L. Coelho-Silva et al., "Naringenin inhibits superoxide anion-induced inflammatory pain: role of oxidative stress, cytokines, nrf-2 and the NO-cGMP-PKG-KATP channel signaling pathway," *PloS One*, vol. 11, no. 4, Article ID e0153005, 2016.

[308] M. F. Manchope, R. Casagrande, and W. A. Verri Jr., "Naringenin: an analgesic and anti-inflammatory citrus flavanone," *Oncotarget*, vol. 8, no. 3, pp. 3766–3767, 2017.

[309] F. A. Pinho-Ribeiro, A. C. Zarpelon, V. Fattori et al., "Naringenin reduces inflammatory pain in mice," *Neuropharmacology*, vol. 105, pp. 508–519, 2016.

[310] F. A. Pinho-Ribeiro, A. C. Zarpelon, S. S. Mizokami et al., "The citrus flavonone naringenin reduces lipopolysaccharide-induced inflammatory pain and leukocyte recruitment by inhibiting NF-κB activation," *The Journal of Nutritional Biochemistry*, vol. 33, pp. 8–14, 2016.

[311] P. Singh, S. Bansal, A. Kuhad, A. Kumar, and K. Chopra, "Naringenin ameliorates diabetic neuropathic pain by modulation of oxidative-nitrosative stress, cytokines and MMP-9 levels," *Food & Function*, vol. 11, no. 5, pp. 4548–4560, 2020.

[312] N. Xue, X. Wu, L. Wu, L. Li, and F. Wang, "Antinociceptive and anti-inflammatory effect of naringenin in different nociceptive and inflammatory mice models," *Life Sciences*, vol. 217, pp. 148–154, 2019.

[313] K. W. Ruiz-Miyazawa, S. M. Borghi, F. A. Pinho-Ribeiro et al., "The citrus flavonone naringenin reduces gout-induced joint pain and inflammation in mice by inhibiting the activation of NFκB and macrophage release of IL-1β," *Journal of Functional Foods*, vol. 48, pp. 106–116, 2018.

[314] J. L. Dallazzen, C. F. da Silva, L. Hamm et al., "Further antinociceptive properties of naringenin on acute and chronic pain in mice," *Natural Product Communications*, vol. 12, no. 9, Article ID 1934578X1701200915, 2017.

[315] Y. Sato, J. X. He, H. Nagai, T. Tani, and T. Akao, "Isoquiritigenin, one of the antispasmodic principles of Glycyrrhiza uralensis roots, acts in the lower part of intestine," *Biological and Pharmaceutical Bulletin*, vol. 30, no. 1, pp. 145–149, 2007.

[316] Y. Shi, D. Wu, Z. Sun et al., "Analgescic and uterine relaxant effects of isolumiquitinigenin, a flavone from Glycyrrhiza glabra," *Phytotherapy Research*, vol. 26, no. 9, pp. 1410–1417, 2012.

[317] N. Jamali-Raeufy, T. Baluchnejadmojarad, M. Roghani, S. Keimasi, and M. Goudarzi, "Iisorhamnetin exerts neuroprotective effects in STZ-induced diabetic rats via attenuation of oxidative stress, inflammation and apoptosis," *Journal of Chemical Neuroanatomy*, vol. 102, Article ID 101079, 2019.

[318] S. H. Kim, J. G. Park, G. H. Sung et al., "Kaempferol, a dietary flavonoid, ameliorates acute inflammatory and nociceptive symptoms in gastritis, pancreatitis, and abdominal pain," *Molecular Nutrition & Food Research*, vol. 59, no. 7, pp. 1400–1405, 2015.

[319] L. Kishore, N. Kaur, and R. Singh, "Effect of kaempferol isolated from seeds of Eruca sativa on changes of pain sensitivity in streptozotocin-induced diabetic neuropathy," *Inflammopharmacology*, vol. 26, no. 4, pp. 993–1003, 2018.

[320] Z. Parveen, Y. Deng, M. K. Saeed, R. Dai, W. Ahamad, and Y. H. Yu, "Anti-inflammatory and analgesic activities of Thesium chinense Turcz extracts and its major flavonoids, kaempferol and kaempferol-3-O-glucoside," *Yakugaku Zasshi*, vol. 127, no. 8, pp. 1275–1279, 2007.

[321] A. Ahangarpour, A. A. Oroojan, L. Khorsandi, R. Shabani, and S. Mofaddami, "Preventive effects of betulinic acid on streptozotocininduced diabetes in diabetic nephropathy..."
 Evidence-Based Complementary and Alternative Medicine

in male mouse,” *Journal of Nephropathology*, vol. 5, no. 4, pp. 128–133, 2016.

[322] S. S. Bellampalli, Y. Ji, A. Moutal et al., “Betulinic acid, derived from the desert lavender *Hyphtis emoryi*, attenuates pachytaxel-, HIV-, and nerve injury-associated peripheral sensory neuropathy via block of N- and T-type calcium channels,” *Pain*, vol. 160, no. 1, pp. 117–135, 2019.

[323] J. Kalra, M. C. Lingaraju, K. Mathesh et al., “Betulinic acid alleviates dextran sulfate sodium-induced colitis and visceral pain in mice,” *Naunyn-Schmiedeberg's Archives of Pharmacology*, vol. 391, no. 3, pp. 285–297, 2018.

[324] B. O. Oyebanji, A. B. Saba, and O. A. Oridupa, “Studies on the anti-inflammatory, analgesic and anti-pyrexic activities of betulinic acid derived from *Tetracera potatoria*,” *African Journal of Traditional, Complementary, and Alternative Medicines*, vol. 11, no. 1, pp. 30–33, 2014.

[325] J. L. Rios and S. Manez, “New pharmacological opportunities for betulinic acid,” *Planta Medica*, vol. 84, no. 1, pp. 8–19, 2018.

[326] P. Yogeeswari and D. Sriram, “Betulinic acid and its derivatives: a review on their biological properties,” *Current Medicinal Chemistry*, vol. 12, no. 6, pp. 657–666, 2005.

[327] S. M. Borghi, F. A. Pinho-Ribeiro, V. Fattori et al., “Quercetin inhibits peripheral and spinal cord nociceptive mechanisms to reduce intense acute swimming-induced muscle pain in mice,” *PloS One*, vol. 11, no. 9, Article ID e0162267, 2016.

[328] C. Calixto-Campos, M. P. Correa, T. T. Carvalho et al., “Quercetin reduces Ehrlich tumor-induced cancer pain in mice,” *Analytical Cellular Pathology (Amsterdam)*, vol. 2015, Article ID 285708, 2015.

[329] G. Carullo, A. R. Cappello, L. Frattaruolo, M. Badolato, B. Armentano, and F. Aiello, “Quercetin and derivatives: useful tools in inflammation and pain management,” *Future Medicinal Chemistry*, vol. 9, no. 1, pp. 79–93, 2017.

[330] A. W. Filho, V. C. Filho, L. Olinger, and M. M. de Souza, “Quercetin: further investigation of its antioxidative properties and mechanisms of action,” *Archives of Pharmacal Research*, vol. 31, no. 6, pp. 713–721, 2008.

[331] Z. Li, J. Zhang, X. Ren, Q. Liu, and X. Yang, “The mechanism of quercetin in regulating osteoclast activation and the PAR2/TRPV1 signaling pathway in the treatment of bone cancer pain,” *International Journal of Clinical and Experimental Pathology*, vol. 11, no. 11, pp. 5149–5156, 2018.

[332] A. L. Martinez, M. E. Gonzalez-Trujano, E. Aguirre-Hernandez, J. Moreno, M. Soto-Hernandez, and F. J. Lopez-Munoz, “Antinociceptive activity of *Tilia americana* var. Mexicana inflorescences and quercetin in the formalin test,” *Neuropharmacology*, vol. 56, no. 2, pp. 564–571, 2009.

[333] D. A. Shoskes and J. C. Nickel, “Quercetin for chronic prostatitis/chronic pelvic pain syndrome,” *Urologic Clinics of North America*, vol. 38, no. 3, pp. 279–284, 2011.

[334] D. A. Valerio, S. R. Geogetti, D. A. Magro et al., “Quercetin reduces inflammatory pain: inhibition of oxidative stress and cytokine production,” *Journal of Natural Products*, vol. 72, no. 11, pp. 1975–1979, 2009.

[335] M. Anjaneyulu and K. Chopra, “Quercetin, a bioflavonoid, attenuates thermal hyperalgesia in a mouse model of diabetic neuropathic pain,” *Prog Neuropsychopharmacol Biol Psychiatry*, vol. 27, no. 6, pp. 1001–1005, 2003.

[336] M. Anjaneyulu and K. Chopra, “Quercetin attenuates thermal hyperalgesia and cold allodynia in STZ-induced diabetic rats,” *Indian Journal of Experimental Biology*, vol. 42, no. 8, pp. 766–769, 2004.

[337] M. I. Azevedo, A. F. Pereira, R. B. Nogueira et al., “The antioxidant effects of the flavonoids rutin and quercetin inhibit oxaliplatin-induced chronic painful peripheral neuropathy,” *Molecular Pain*, vol. 9, p. 53, 2013.

[338] K. Dureshahwar, M. Mushbir, and H. D. Une, “Quantification of quercetin obtained from *Allium cepa* Lam. leaves and its effects on streptozotocin-induced diabetic neuropathy,” *Pharmacognosy Research*, vol. 9, no. 3, pp. 287–293, 2017.

[339] P. E. Ferreira, C. R. Lopes, A. M. Alves et al., “Diabetic neuropathy: an evaluation of the use of quercetin in the cecum of rats,” *World Journal of Gastroenterology*, vol. 19, no. 38, pp. 6416–6426, 2013.

[340] W. Gao, Y. Zan, Z. J. Wang, X. Y. Hu, and F. Huang, “Quercetin ameliorates pachytaxel-induced neuropathic pain by stabilizing mast cells, and subsequently blocking PKC-dependent activation of TRPV1,” *Acta Pharmacologica Sinica*, vol. 37, no. 9, pp. 1166–1177, 2016.

[341] C. Ji, Y. Xu, F. Han et al., “Quercetin alleviates thermal and cold hyperalgesia in a rat neuropathic pain model by inhibiting Toll-like receptor signaling,” *Biomedicine & Pharmacotherapy*, vol. 94, pp. 652–658, 2017.

[342] N. Muto, Y. Matsuoka, K. Arakawa et al., “Quercetin attenuates neuropathic pain in rats with spared nerve injury,” *Acta Medica Okayama*, vol. 72, no. 5, pp. 457–465, 2018.

[343] P. S. Naidu, A. Singh, and S. K. Kulkarni, “D2-dopamine receptor and alpha2-adrenoreceptor-mediated analgesic response of quercetin,” *Indian Journal of Experimental Biology*, vol. 41, no. 12, pp. 1400–1404, 2003.

[344] K. S. Raygude, A. D. Kandhare, P. Ghosh, A. E. Ghule, and S. L. Bodhankar, “Evaluation of ameliorative effect of quercetin in experimental model of alcoholic neuropathy in rats,” *Inflammopharmacology*, vol. 20, no. 6, pp. 331–341, 2012.

[345] J. Xie, W. Song, X. Liang et al., “Protective effect of quercetin on streptozotocin-induced diabetic peripheral neuropathy rats through modulating gut microbiota and reactive oxygen species level,” *Biomedicine & Pharmacotherapy*, vol. 127, Article ID 110147, 2020.

[346] R. Yang, L. Li, H. Yuan et al., “Quercetin relieved diabetic neuropathic pain by inhibiting upregulated P2X4 receptor in dorsal root ganglia,” *Journal of Cellular Physiology*, vol. 234, no. 3, pp. 2756–2764, 2019.

[347] A. D. Kandhare, K. S. Raygude, V. S. Kumar et al., “Ameliorative effects quercetin against impaired motor nerve function, inflammatory mediators and apoptosis in neonatal streptozotocin-induced diabetic neuropathy in rats,” *Biology and Aging Pathology*, vol. 2, no. 4, pp. 173–186, 2012.

[348] O. B. Acikara, G. S. Citoglu, S. Dall'Acqua et al., “Bioassay-guided isolation of the antinociceptive compounds motiol and beta-sitosterol from *Scorzonera latifolia* root extract,” *Pharmazie*, vol. 69, no. 9, pp. 711–714, 2014.

[349] N. Das, A. Bhattacharya, S. Kumar Mandal et al., “*Ichnocarpus frutescens* (L.) R. Br. root derived phyto-steroids defends inflammation and algesia by pulling down the pro-inflammatory and nociceptive pain mediators: an in-vitro and in-vivo appraisal,” *Steroids*, vol. 139, pp. 18–27, 2018.

[350] M. E. Hernandez-Flores, J. M. Torres-Valencia, R. Carinocortes et al., “In search of safe pain relief: the analgesic and anti-inflammatory activity of phytosteryl ibuprofenates,” *Steroids*, vol. 149, Article ID 108420, 2019.
[351] S. A. Nirmal, S. C. Pal, S. C. Mandal, and A. N. Patil, “Analgesic and anti-inflammatory activity of beta-sitosterol isolated from Nyctanthes arbor-tristis leaves,” Inflammopharmacology, vol. 20, no. 4, pp. 219–224, 2012.

[352] R. Paniagua-Perez, G. Flores-Mondragon, C. Reyes-Legorreta et al., “Evaluation of the anti-inflammatory capacity of beta-sitosterol in rodent assays,” African Journal of Traditional, Complementary, and Alternative Medicines, vol. 14, no. 1, pp. 123–130, 2017.

[353] A. R. Santos, R. Niero, V. C. Filho et al., “Antinociceptive properties of steroids isolated from Phyllanthus corcovadensis in mice,” Planta Medica, vol. 61, no. 4, pp. 329–332, 1995.

[354] W. P. Battisti, N. P. Katz, A. L. Weaver et al., “Pain management in osteoarthritis: a focus on onset of efficacy—a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials,” Journal of Pain, vol. 5, no. 9, pp. 511–520, 2004.